Immunoregulation and the Role of IL-17
During Chronic Pulmonary Exposure to Aspergillus fumigatus

by

Benjamin Joseph Murdock

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Immunology)
in The University of Michigan
2010

Doctoral Committee:
Professor Gary B. Huffnagle, co-chair
Assistant Professor Eric S. White, co-chair
Professor David A. Fox
Professor Nicholas W. Lukacs
Professor Marc Peters-Golden
To Penney and Owen
Acknowledgments

First and foremost I would like to thank my thesis advisers, Gary Huffnagle and Eric White, for their guidance and support in reaching this particular mountaintop in my life. They have each in their own way provided encouragement when it was warranted and a swift kick in the ass when it was needed. They provided a home for me when I was homeless and were nice enough not to toss me back out onto the street when my first project didn’t pan out. I salute both of your dedication to the sciences, dedication to students of the sciences, and your endless patience with both. Most of all I would like to thank you for the time you spent preparing me to be a scientist: not only did I learn base technique but I learned the mindset needed to accompany it. I would bid farewell, but chances are excellent that I will be working with you still even after I graduate. Like a family that feeds a stray animal who then refuses to leave, I doubt you knew what you were getting into when you took me in.

I would like to thank members of the Huffnagle and White labs, both past and present:

· Andrew Shreiner who laid the very foundation of my work and set a superb example for someone trying to balance the stresses of science and child-rearing.

· John Erb-Downward for knowing everything about anything and having the patience to explain it all.
· Nicole Falkowski who is the best lab manager a lab could ever want. How we managed to survive her seemingly endless maternity leave is a question not even science can answer.

· Roderick McDonald for steady hands, a dry wit, and an unflappable nature even when wrist-deep in mouse surgeries.

· Mei Yan for her sly wit, imperturbable nature, and unparalleled organization skills.

· Rommel Sagana for moral support and engaging conversation.

· Katie Mason for being my source of sanity in the storm. And putting up with my jokes.

· Adam Booth for being an inexhaustible source of information and feedback, as well as the finer points of parenting. The witty repartee doesn’t hurt either.

· Ashley Cornett for her charm, constant pluck, and exceptional organizational skills.

· Merritt Gillilland III for his humor, feedback, and a name that lends itself to endless jokes.

· Gwo-Hsiao Chen for being one of my first mentors in the lab and for his eternally sunny disposition.

· John Osterholzer for answering all of my questions, no matter how banal.

· Michael Shen for insights into the dark, unseemly world of MDs.

· Mary Pat Craver who provided a wealth of information during her brief tenure.

· Kelly Mason and her diligence and eternal patience with undergrad grunt work.

· Anoop Nambiar for teaching me that you can lead a horse to water but you can’t make him like bench work.
I also would like to thank the members of my thesis committee, David A. Fox, Nicholas Lukacs, and Marc Peters-Golden for their insights, feedback, and sometimes scathing criticism. It was never easy, but then it was never meant to be. Thank you for your help in making me a better scientist.

I would like to thank various faculty members for their role in shaping my project and offering constructive criticism. Galen Toews: thank you for both the honest critiques as well as exceptionally detailed explanations. Both were indispensable. Tom Moore: you were always ready with a much-needed opinion or explanation. And nobody does tail vein injections as well as you do. John Osterholzer: thanks for all the help with cellular characterization. Vince Young, John Kao, Michal Olszewski, and Mary O’Riordan: you always made lab meetings touch-and-go. It was hair-raising but I’m better for it.

I would like to thank Keith Bishop for his role as director of the Graduate Program in Immunology, as well as his constructive criticism and honest feedback.

I would like to thank Zarinah Aquil, current immunology student services coordinator, and Ellen Elkin the previous coordinator who has since left for bigger and better things. You both have made the difficult seem easy and the crazy seem sane. The program, nay the world, very well might fly apart without your guidance.

I would like to thank Lilli Petruzzelli, my former mentor, for teaching me to be strong and independent. As they say, what doesn’t kill you makes you stronger.

I would like to thank my friends within the program who are too numerous to name here. No man is an island, and I am certainly no exception.

I would like to thank my wife’s family: my mother-in-law Judy for her support and constant babysitting, my brother-in-law Joe for his laconic wit and handy-man
expertise, and my sister-in-law Jacqui for her bubbly nature and seemingly endless supply of wonderfully tasteless jokes.

I would like to thank my parents for love and guidance, as well as financial support and free meals. I couldn’t have gotten to grad school without you, and I doubt I could have made it through without you either. Thank you for twenty-nine years of pep-talks, punishments, and constructive criticism, all given when needed. Being a parent myself makes me appreciate your dedication and sacrifices all the more.

I would like to thank my precocious son, Owen, for teaching me more in two and a half years than probably the rest of my life combined. You’re always waiting for me at home with a hug, a kiss, and a huge grin. I doubt it’s a coincidence that things started working in lab right when you were born.

Finally, I would like to thank my wife and partner in crime, Penney. She is both my biggest fan and harshest critic. She kicks my butt into gear when something needs to be done and soothes my frazzled nerves when things are falling apart. She is a mother, a wife, a lover, and a friend, and I in no way shape or form could have made it here without her. Thanks, babe.
Table of Contents

Dedication.........................................................................................................................ii
Acknowledgements.............................................................................................................iii
List of Figures....................................................................................................................viii
List of Appendices.............................................................................................................xi
List of Abbreviations.........................................................................................................xii

Chapter 1
  Background.........................................................................................................................1

Chapter 2
  Methods............................................................................................................................32

Chapter 3
  Characterizing the Hypersensitivity Response ...............................................................40

Chapter 4
  The Role of IL-17 in Hypersensitivity ..............................................................................74

Chapter 5
  The Role of IL-17 in Eosinophil Development, Maturation, and Trafficking...............99

Chapter 6
  Summary, Interpretation, Critical Review, and Future Directions.................................126

Appendices........................................................................................................................143
List of Figures

Figure
1-1 Development and regulation of CD4 T cells………………………………………13
3-1 Conidia introduced via weekly intranasal challenge do not induce death and can be detected twenty-four hours after exposure. .................................52
3-2 Hypersensitivity in the lung is accompanied by cellular infiltrate around the airways and mucus hyper-secretion. ..............................53
3-3 Repeated intranasal exposure to Aspergillus fumigatus conidia generates a hypersensitivity response in C57BL/6 mice. .................................54
3-4 Subsets of myeloid cells within the lung have distinct expression patterns of cell surface markers. .................................................................55
3-5 Subpopulations do not consist of alternatively activated macrophages or natural killer cells. .................................................................56
3-6 New cells are recruited to the lung during peak inflammation...............57
3-7 Basophil numbers significantly increase during the hypersensitivity response.................................................................58
3-8 CD4 T cells are activated in response to A. fumigatus conidia in the lung but not the lymph node. .................................................................59
3-9 The percentage of CD4 T cells displaying a regulatory phenotype increases during the early immune response, but total numbers increase over the course of exposure. .................................................................60
3-10 Each stage of the immune response to A. fumigatus displays a distinct CD4 cytokine profile in the lung. .................................................................61
3-11 Poor clearance of conidia is positively associated with specific cell populations during peak inflammation. .................................................................62
3-12 Repeated exposure to low levels of pulmonary exposure conidia results in hypersensitivity and a dynamic immune response. ......................63
IL-17−/− do not have increased susceptibility to lethal fungal infection……..81

Lack of IL-17 abrogates hypersensitivity response but does not dampen the chronic inflammatory response. .................................................................82

Basophil levels are unaffected by the lack of IL-17 during acute and chronic inflammation. .................................................................83

IL-17−/− mice show reduced cellular infiltrate but are still capable of mucus-hyper-secretion and multi-nucleated macrophage formation...............84

Reduced eosinophil infiltrate can be observed in IL-17−/− mice following four challenges with Af conidia. .................................................................85

T cell activation is unaffected in IL-17−/− mice, but there is a decrease in the CD4 regulatory phenotype following two challenges.........................86

IL-17−/− mice do not produce IL-10 in response to initial conidia challenges..87

IL-17−/− mice have enhanced clearance of conidia following four and eight challenges. .................................................................88

Cell numbers do not correlate with conidia clearance in IL-17−/− mice during peak inflammation. .................................................................89

WT and IL-17−/− mice show identical bone marrow differentiation in response to repeated pulmonary conidia challenge. ........................................107

Bone marrow differentiation is unchanged in IL-17−/− mice during peak inflammation. .................................................................108

WT and IL-17−/− mice bone marrow shows no obvious phenotypic differences following chronic exposure to conidia. ........................................109

Bone marrow from IL-17−/− mice shows a significant reduction in production of GATA-1 mRNA. .................................................................110

Lung eosinophils show increased maturity in response to antigen challenge.................................................................111

Lung eosinophils maturity is unaffected by a lack of IL-17......................112

Expression of siglec F on eosinophils is governed by cell maturity and is unaffected by fungal exposure or the presence of IL-17.........................113

Lack of IL-17 does not alter myeloid activation but reduces the influx of new cells into the lung. .................................................................114
IL-17⁻/⁻ mice show increased numbers of eosinophils and other myeloid cells in the blood during peak inflammation.

IL-17⁻/⁻ mice are predicted to have less IL-5 in the lungs during peak inflammation.
List of Appendices

Appendix 1
   CD4 T Cells are Not the Sole Contributors of IL-17 ..........................143
Appendix 2
   Protocols and Odds and Ends .........................................................148
## List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAMΦ</td>
<td>alternatively-activated macrophage</td>
</tr>
<tr>
<td>Af</td>
<td><em>Aspergillus fumigatus</em></td>
</tr>
<tr>
<td>APC</td>
<td>antigen presenting cell</td>
</tr>
<tr>
<td>BM</td>
<td>bone marrow</td>
</tr>
<tr>
<td>CCR</td>
<td>C-C motif receptor</td>
</tr>
<tr>
<td>CXCR</td>
<td>CXC chemokine receptor</td>
</tr>
<tr>
<td>DC</td>
<td>dendritic cell</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>FACS</td>
<td>fluorescent-activated cell sorting</td>
</tr>
<tr>
<td>FcR</td>
<td>Fragment, crystalizable (region) receptor</td>
</tr>
<tr>
<td>FSC</td>
<td>forward-scatter</td>
</tr>
<tr>
<td>IDO</td>
<td>indoleamine-2,3-dioxygenase</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon</td>
</tr>
<tr>
<td>IL</td>
<td>interleukin</td>
</tr>
<tr>
<td>IL-17*/-</td>
<td>IL-17 knockout</td>
</tr>
<tr>
<td>LN</td>
<td>lymph node</td>
</tr>
<tr>
<td>MΦ</td>
<td>macrophage</td>
</tr>
<tr>
<td>MACS</td>
<td>magnetic-activated cell sorting</td>
</tr>
<tr>
<td>MBP</td>
<td>major basic protein</td>
</tr>
<tr>
<td>OVA</td>
<td>ovalbumin</td>
</tr>
<tr>
<td>PAMP</td>
<td>pathogen-associated molecular pattern</td>
</tr>
<tr>
<td>PAS</td>
<td>periodic acid-Schiff</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate buffer saline</td>
</tr>
<tr>
<td>PRR</td>
<td>pattern-recognition receptor</td>
</tr>
<tr>
<td>sigF</td>
<td>siglec F</td>
</tr>
<tr>
<td>SSC</td>
<td>side-scatter</td>
</tr>
<tr>
<td>TGF</td>
<td>transforming growth factor</td>
</tr>
<tr>
<td>TH</td>
<td>T helper</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-like receptor</td>
</tr>
<tr>
<td>TNF</td>
<td>tumor necrosis factor</td>
</tr>
<tr>
<td>T&lt;sub&gt;reg&lt;/sub&gt;</td>
<td>regulatory T cell</td>
</tr>
<tr>
<td>WT</td>
<td>wild-type</td>
</tr>
</tbody>
</table>
Chapter 1
Background

Allergic airway disease is a chronic inflammatory condition characterized by airway hyperresponsiveness and reversible airway obstruction in response to repeated antigenic stimulation (1). The literature cites numerous sources and possible sources of disease: viruses (2, 3), allergens (4), and occupational compounds (5) have been implicated as potential sources, while a wide variety of factors from viruses, to common bacteria (6), to sex hormones (7) have been shown to help drive the initial allergic response. Of particular interest is hypersensitivity to fungi (8), as 20-25% of asthmatics are skin-test positive towards fungal allergens (9, 10), and there is a strong correlation between sensitivity to fungal allergens and disease severity (11).

Fungi and Disease

*Aspergillus fumigatus*, an airborne fungus, is the focus of extensive research due to its ubiquitous nature. *A. fumigatus* disseminates itself via conidia – hydrophobic (12, 13) spores which are readily and frequently inhaled into airways (14) – and large doses are not uncommon (15). Once the conidia reach a warm, moist environment such as the lungs, they lose their hydrophobic properties (16) and begin to germinate, express genes, and generate structural components (17). The conidia first swell, then extend germ tubes, and finally develop invasive hyphae (18). Even relatively large doses of conidia pose
little threat to immunocompetent individuals, however, as macrophages and neutrophils efficiently neutralize germinating conidia in the lung (19, 20), and resting conidia are cleared from the lung by macrophages without the induction of an inflammatory response (21, 22).

Therefore *A. fumigatus* typically causes disease in one of two ways: by infecting immunocompromised individuals or by inducing a hypersensitivity reaction in healthy individuals through repeated exposures or colonization. In individuals with compromised immune systems – from organ transplantation (23, 24), HIV infection (25), or steroid therapy (19), for example – a lack of immune response leads to incomplete *A. fumigatus* killing (26) and can facilitate fungal invasion of the tissue (27). On the other hand, hypersensitivity can occur when the immune system is primed towards *A. fumigatus* antigens and mounts an inappropriate response. Hypersensitivity pneumonitis (28, 29) and allergic asthma (9, 10, 30) resulting from repeated *A. fumigatus* exposure are both examples of this phenomenon.

There are a number of anti-fungal treatments used to counter *A. fumigatus* and other invasive fungi by enhancing or augmenting the host immune system or by killing the fungus outright. Examples include Voriconazole (31-33), Amphotericin B (33, 34), Pentraxin 3 (35), and new lipopeptides (36). However, such therapies often have unwanted side-effects and are geared primarily at countering invasive fungal disease rather than hypersensitivity. In the end, pulmonary hypersensitivity is not a fungal disease but an *immune* disease, and adequate clinical treatment will require a more thorough understanding of the immune response to *A. fumigatus*.

**Model of Hypersensitivity**
Our laboratory has designed a model of *Aspergillus fumigatus*-induced pulmonary hypersensitivity based on previous observations by Mairi Noverr, Tobias Rodriguez, and Andrew Shreiner. Repeated exposure to *A. fumigatus* conidia in wild-type C57BL/6 mice generates a hypersensitivity response that is CD4 T cell-dependent (37). This response is characterized by the production of T$_{h2}$-type cytokines, eosinophilia, mucus hypersecretion, and tissue remodeling.

The standard model of T$_{h2}$-type pulmonary hypersensitivity involves sensitization and challenge of mice with ovalbumin (OVA). Variations of this model involve sensitization with adjuvants (38, 39), immunization routes (39-41), and genetic background (42-47) which result in a wide and inconsistent spectrum of immune responses (48). In addition, the OVA model, while informative, is not necessarily physiologically relevant as it does not mimic environmental conditions that result in pulmonary hypersensitivity. Our *A. fumigatus* model, on the other hand, is both physiologically relevant and provides a consistent response among genetic backgrounds.

**Innate Immune Response to Aspergillus Fumigatus**

The immune response to *A. fumigatus* is characterized by complex interactions between the innate immune response and the adaptive immune response, both of which are quickly activated by the presence of fungi (24, 27). The reaction must be complex, because *Af* is not an inert particle but a dynamic organism capable of reacting to its environment and even the host immune system (49). The innate immune system acts as the first line of defense against pathogens and encounters an exceptionally wide array of microbes and particles (50-52). In the case of *Aspergillus fumigatus*, a complex collection of cells types, pathways, and cytokines compromise the initial reaction to germinating
conidia and developing hyphae. Macrophages (53), neutrophils (54), dendritic cells (55), monocytes (56), eosinophils (57), natural killer cells (58) all play a role in host defense, as do aspects of the complement system (59) such as mannan-binding lectin (60) and Pentraxin 3 (35).

**Macrophages** are the primary cells responsible for clearing *A. fumigatus* conidia from the lung. Macrophages bind the conidia with DC-SIGN, a lectin-like attachment site (53, 61) and engulf *A. fumigatus* in an oxidase-dependant manner (14). When low numbers of conidia enter the lungs, alveolar macrophages quickly and efficiently phagocytize and kill conidia before the spores can germinate, neutralizing any potential threat without triggering an inflammatory response (21, 22). Greater numbers of conidia may necessitate an aggressive inflammatory response, but macrophages are still an essential factor in host defense. Both macrophages and dendritic cells bind *A. fumigatus* in the early stages of infection (53); inhibition of macrophage function allows conidia to germinate and hyphae to form (19, 62). Moreover, alveolar macrophages can activate and produce cytokines independently of toll-like receptor (TLR) signaling (63, 64), perhaps in response to the ability of *A. fumigatus* to dampen TLR2 and TLR4 signaling (65). This independence is restricted to alveolar macrophages, however, and macrophages from other sites are typically TLR- and MyD88-dependent (66, 67).

Similar to macrophages, **dendritic cells** bind *A. fumigatus* in the early stages of infection but can also initiate an adaptive immune response by trafficking to the mediastinal lymph node to induce T cell activation (55). Dendritic cells can consume fungi through several mechanisms and even discriminate between fungal stages, with distinct subpopulations showing different roles in fungal defense (68). Dendritic cells seem to act as a central fulcrum for the adaptive immune response, dictating which T
helper (T\textsubscript{H}) responses will be used. Dendritic cells can balance T\textsubscript{H}1 and T\textsubscript{H}2 via IL-12 and IL-13 (69), and dendritic cells activated through dectin-1 – a pathogen-associated molecular pattern (PAMP) receptor – can induce a T\textsubscript{H}17 response (70) and even convert regulatory T cells into T\textsubscript{H}17 effector cells (71). In addition, monocytes, often overlooked in inflammatory responses, have a significant role in the clearance of \textit{Aspergillus} from the lung by facilitating a T cell response (56). They respond to a number of different pathogens (72), and like dendritic cells they are not homogenous (73, 74), with different subgroups producing TNF or inhibiting germination of \textit{A. fumigatus} (75).

Once an inflammatory response has been initiated, neutrophils become the primary defense against invasive aspergillosis. Neutrophils are essential during an acute response to \textit{A. fumigatus} (54) and are even more essential than macrophages during early infection (76). Neutrophils restrict hyphal invasion of local tissue, and poor activation or influx of neutrophils is associated with invasive aspergillosis (62, 77). Neutrophils help control \textit{Aspergillus} infection via traditional phagocytosis and cytokine release, but they are also capable of releasing Pentraxin 3 lectin (78). In addition, they can form neutrophil extracellular traps in response to both conidia and hyphae (79), though the signaling mechanism for this process is not well understood. Both the activity and total numbers of neutrophils are tightly regulated by multiple mechanisms, as neutrophils have the capacity to cause significant amounts of damage to inflamed tissue (80, 81).

\textbf{Eosinophils} also respond to \textit{Aspergillus fumigatus}-induced inflammation, and like neutrophils they are tightly regulated due to their potential for tissue damage. They have been implicated in a number of inflammatory defense processes towards helminths, bacteria, viruses, fungi, injured tissue, and tumors, but have also been implicated in several forms of immune dysregulation such as allergies and pulmonary remodeling (82).
Eosinophils are multi-functional; they express TLRs (83), act as antigen presenting cells (84), and secrete over thirty different inflammatory and regulatory cytokines (85, 86), including T\textsubscript{H}1-associated cytokines (87-89). Unlike T cells, eosinophils store cytokines in granules and release them at inflammatory sites rather than generating them de novo (90). This allows a rapid response against potential pathogens, though the release of cytokines stored in granulocytes is regulated by the local milieu. Against \textit{A. fumigatus}, eosinophils react to the β-glucan subunits expressed in germinating conidia (57), but their primary role seems to be combating invasive fungal hyphae that have already established a foothold within the host tissue.

A key component of the innate response is the expression of \textit{indoleamine-2,3-dioxygenase (IDO)} (91). IDO is a metabolic enzyme that catabolizes L-tryptophan to N-formylkynurenine, the process of which can suppress the proliferation and activity of immune cells as well as microbes. Its expression is highly responsive to the immune system (92), and it exerts a significant, corresponding effect on the immune system, particularly neutrophils (93). IDO plays a complex role in the control of both the innate and adaptive immune responses; IDO is upregulated by proinflammatory cytokines and IFN-γ (94), but it simultaneously drives the generation of regulatory T cells (T\textsubscript{reg}) (95). Moreover, lack of IDO abrogates T\textsubscript{H}2 hypersensitivity in the lung (96), and allergy – via IDO production – can be controlled through glucocorticoid-induced tumor necrosis factor receptor (GITR) (97), a surface receptor frequently associated with regulatory T cell function. Eosinophils constitutively express IDO, and it is possible that they use IDO-mediated suppression of the T\textsubscript{H}1 to maintain a T\textsubscript{H}2-type immune response (98). To further complicate matters, T\textsubscript{H}17 cells also inhibit IDO expression through IL-17 and IL-
23 (94) and can negatively affect clearance os A. fumigatus from the lung by altering the inflammatory program of neutrophils (99).

The major method of by which the immune system is activated is the use of PAMP receptors such as **toll-like receptors (TLRs)** and **dectin-1** (100). *Aspergillus fumigatus* expresses a number of ligands for PAMP receptors including chitin, β-glucans, and galactomannan (101). Moreover, TLR polymorphisms affect susceptibility to invasive fungal disease (102), highlighting the central role of TLRs in fungal defense. Mice deficient in TLR and MyD88 – the primary adapter protein for TLR signaling – can survive inhaled *A. fumigatus* conidia but at a lower rate than wild-type mice (103), and MyD88 signaling is particularly important in the early pulmonary response to *Aspergillus* (104) due to its control of neutrophil activity (54). PAMP receptors can have a pathogenic role in disease, however, as TLR signaling has been implicated in chronic inflammation (105), and dectin-1 can drive a potentially autoimmune-inducing TH17 response (106). On the other hand, repeated TLR signaling can lead to hyporesponsiveness as has been found with TLR2 (107), TLR5 (108), TLR7, TLR8 (109), and TLR9 (110).

In response to *Aspergillus fumigatus*, TLR2 and TLR4 play a central role (111, 112). There is a synergistic effect between both receptors (113), and a blockade of the TLRs reduces TNF-α levels during *A. fumigatus* infection (114). Both are capable of activating macrophages during infection (115), though macrophages can also be activated in a TLR-independent manner (64). TLR2 can stimulate both TH2 responses (116, 117) as well as the induction and expansion of regulatory T cell populations (118, 119). TLR2 is involved in the immune response to both conidia and hyphae (115) while TLR4 induces the response to conidia only (120). It’s therefore likely that TLR4 plays a more prominent
role in early *A. fumigatus* infection while TLR2 acts during late fungal invasion. TLR9 may also be activated by Pentraxin 3 (35), and various references have shown that *A. fumigatus* can with TLRs 1, 3, 6, and 10 on neutrophils as well (54).

Also playing a key role in innate and adaptive immunity to *A. fumigatus* is dectin-1, a PAMP receptor which has been shown to play an essential role in the control of fungal infections (121). Originally dectin-1 was thought to be expressed primarily by monocytes, macrophages, and neutrophils (122), but one recent study has shown a significant role for dectin-1 signaling in dendritic cells in response to *A. fumigatus* (123).

The primary role of dectin-1 is the binding of β-glucan, an essential component of germinating conidia (124, 125), and like other PAMP receptors it is capable of triggering phagocytosis, inflammation, and cytokine release (126-128). One notable characteristic of dectin-1 is its ability to enhance TLR signaling (129). In fact, dectin-1 is dependent on TLR signaling, as dectin-1/TLR collaboration via the Syk kinase is required for proper signaling (130), and in monocytes and macrophages dectin-1 works with TLR2 and TLR4 to induce cytokine production (131). Dectin-1 signaling results in a myriad of different cytokines and adaptive immune pathways: dectin-1 can activate the cytotoxic T cell response (132), can regulate downregulate IL-12 and upregulate IL-23 (133), can generate IL-2 and IL-10 production (106), can induce regulatory T cell differentiation and tolerance (118), can promote a Th17-type response via IL-6 and IL-23 production (106, 134), and can induce dendritic cells to convert Treg to Th17 cells (71).

The Adaptive Immune Response

Though the innate immune response plays a central role in immunity to *Aspergillus fumigatus*, equally important is the adaptive immune response. Similar to
the innate immune response, the adaptive immune response is activated quickly by *A. fumigatus* (24, 27). Traditionally, the adaptive immune response was viewed as a balance between the response to intracellular pathogens (T\textsubscript{H}1) (135) and the response to parasites (T\textsubscript{H}2) (136). In the last few years the regulatory and T\textsubscript{H}17 responses have added an additional layer of complexity to our understanding of the adaptive immune response (Fig. 1-1). During the response to *A. fumigatus*, all four of the major arms of the adaptive response can be engaged depending on the viability of the conidia (137), which fungal components are present (138), or, as we will see shortly, how long the host has been exposed to the organism.

The T\textsubscript{H}1 adaptive immune response has been repeatedly shown to be of great importance in defense against invasive *A. fumigatus*. Progressive invasion of infected tissue has been associated with decreased IFN-\(\gamma\) production and poor T cell proliferation (139), and inhibition of IFN-\(\gamma\) and TNF-\(\alpha\) enhance fungal invasion (140, 141). In reaction to inhalation, the T\textsubscript{H}1 response peaks one week after initial infection (137) and IFN-\(\gamma\) production is capable of inhibiting early T\textsubscript{H}2 hypersensitivity (142). Dendritic cells in particular appear to play a major role in driving the T\textsubscript{H}1 defense against *A. fumigatus* (143). Conidia inhalation results in the expression of TNF-\(\alpha\), IFN-\(\gamma\), IL-12, and IL-18 (144). These cytokines play a variety of roles in this anti-fungal response: TNF-\(\alpha\) drives neutrophil recruitment (145), IFN-\(\gamma\) and GM-CSF enhances the fungal killing by neutrophils (146, 147), IL-12 helps fight fungal invasion (148, 149), and IL-18 sustains the T\textsubscript{H}1 anti-fungal response (150). In addition, IL-6 and IL-15 have been shown to play roles in the T\textsubscript{H}1 defense against *A. fumigatus*, both by enhancing the neutrophil response to the infection (151-153).
Antagonistic to the T\textsubscript{H1} pathway (154) is the T\textsubscript{H2} pathway, which provides host defense against parasites and extracellular pathogens (155). \textit{A. fumigatus} antigens are capable of inducing a T\textsubscript{H2} type response, though it is hyphal extracts and not conidia that do so (156). This supports the observation that the T\textsubscript{H2} response is dependent on high levels of fungal growth (157) though, oddly, killed fungal spores result in more IL-4 and IL-13 production than live conidia (137). The presence of a T\textsubscript{H2} response is most likely useful in combating late-stage fungal invasion, but its presence can have a number of unwanted effects. IL-4, IL-5, and IL-13 made in response to fungi can result in asthma (158, 159), and eosinophils, like neutrophils, can cause damage to tissue at the site of inflammation (80, 81). Moreover, early T\textsubscript{H2} cytokines such as IL-4 can dampen the T\textsubscript{H1} response and increase susceptibility to \textit{Aspergillus} (160). Aside from the classic T\textsubscript{H2} cytokines, IL-25 is also emerging as a major player in the T\textsubscript{H2} pathway: IL-25 can control T\textsubscript{H2} memory cells (161), as it can drive (162), regulate (163), and amplify the T\textsubscript{H2} response (164, 165).

A third factor in the adaptive immune response to \textit{Aspergillus fumigatus} is the recently discovered T\textsubscript{H17} response. Though the signature cytokine of T\textsubscript{H17}, IL-17A (also known simply as IL-17), was first discovered in 1995 (166), it wasn’t until 2005 that researchers recognized that T\textsubscript{H17} was a wholly separate branch of adaptive immunity (167, 168). Since then T\textsubscript{H17} has become the focus of intense study, with many speculating that it serves as a bridge between the innate and adaptive immune responses (169). A wide array of microbes induces T\textsubscript{H17}, and in response T\textsubscript{H17} T cells can produce and induce a wide array of cytokines (170). Similar to T\textsubscript{H2}, T\textsubscript{H17} and T\textsubscript{H1} are reciprocally regulated (167, 171); also similar to T\textsubscript{H2}, T\textsubscript{H17} has been linked to a number of immune diseases. In particular, T\textsubscript{H17} has been implicated in forms of autoimmunity.
that were once considered \( \text{T}_1 \) disorders (172). Likewise, many disorders that were once considered to be \( \text{T}_2 \) mediated are now being reassessed. It has been found that IL-17 levels correlate with allergy severity (173) and are increased in human asthma (174, 175). In particular, IL-17 affects neutrophil recruitment during asthma and other inflammatory diseases (176), though it has also been shown that IL-17 can be a negative regulator of asthma in mice (39). In general, \( \text{T}_{17} \) may worsen inflammation by downregulating IDO and the \( \text{T}_{\text{reg}} \) response (177). That being said, the \( \text{T}_{17} \) response has demonstrated a number of protective effects (178) including defense against systemic candidiasis (179), and in the absence of a \( \text{T}_1 \) response the \( \text{T}_{17} \) is often the most viable alternative (99). In particular, IL-17 can upregulate the expression of TLRs (180), and IL-22 – another \( \text{T}_{17} \) cytokine – is capable of upregulating the innate immune response (181-183).

Against \( A. \ fumigatus \ \text{T}_{17} \) plays a major role in deciding the composition of the immune response. Though it play a role in driving some anti-fungal components of the immune system (184-187), the \( \text{T}_{17} \) response’s major role seems to be inhibiting \( \text{T}_1 \) and \( \text{T}_{\text{reg}} \) function and preventing proper clearance of germinating conidia. IL-23 and IL-17 have both been shown to promote inflammation while simultaneously inhibiting fungal resistance (99, 188). Structural components of the \( A. \ fumigatus \) cell are largely responsible for this process: dectin-1 binding of these ligands induces a \( \text{T}_{17} \) – but not a \( \text{T}_1 \) – response in dendritic cells (70, 134).

Finally, regulatory T cells (\( \text{T}_{\text{reg}} \)) play a central role in controlling the immune response to foreign microbes such \( A. \ fumigatus \). \( \text{T}_{\text{reg}} \) – which are maintained by the Foxp3 transcription factor (189, 190) – are capable of dampening inflammation caused by \( \text{T}_1 \) (191, 192), \( \text{T}_2 \) (193, 194), and \( \text{T}_{17} \) (190, 195, 196) CD4 T cells. Interestingly, \( \text{T}_{\text{reg}} \) have been shown to play a role in limiting inflammation during the immune response to
Aspergillus fumigatus. The regulatory response towards Af occurs early in the infection (94) and is most likely induced by components of the fungal cell wall binding TLR2 and dectin-1 (118). The reason for the induction of the regulatory response is not entirely clear, though at least one report suggests that limiting inflammation may aid in fungal clearance (197).

Recent reports have added extra depth to our understanding of T_{reg}, particularly the similar manner in which T_{reg} and T_{H17} CD4 T cells arise and are regulated. The two cell types reciprocally develop (198) and Foxp3 and ROR-γτ – the primary transcription factor for T_{H17} CD4 T cells – are mutually antagonistic (199, 200). In mice both cell types arise from naïve CD4 T cells exposed to TGF-β, though the presence of IL-10 skews differentiation towards T_{reg} while IL-6 drives the generation of T_{H17} (201). Surprisingly, it has been recently demonstrated that regulatory T cells are capable of converting to T_{H17} T cells under certain conditions (202, 203). The T_{reg}/T_{H17} balance appears to be controlled by retinoic acid (204) which induces Treg formation (205) as well as IDO which blocks the conversion of T_{reg} to T_{H17} (206, 207).
**Figure 1-1. Development and regulation of the CD4 T cells.** $T_H^1$, $T_H^2$, $T_H^{17}$, and $T_{reg}$ develop from naïve T cells (black arrows). $T_{reg}$ can further develop into $T_H^{17}$ which can develop into $T_H^1$. $T_{reg}$ can inhibit the activity of all three effector cells types, and $T_H^1$ and $T_H^2$ are reciprocally regulated. $T_H^{17}$ has been shown to inhibit $T_H^1$ activity, and $T_H^1$ and $T_H^2$ CD4 T cells are capable of hindering $T_H^{17}$ development but not activity. Also listed are major cytokines of each $T_H$ type.
Hypothesis

We hypothesize that IL-17 plays a role in driving chronic allergic inflammation in the lung during repeated exposure to *Aspergillus fumigatus*. Thus, we believe that removal of IL-17 will abrogate inflammation after the initial T\(_{H2}\)-driven hypersensitivity response.

Study Objectives

1. To characterize the immune response to *Aspergillus fumigatus* conidia during the acute and chronic phases of inflammation
2. To determine the role of IL-17 during the hypersensitivity response to *Af* conidia.
3. To determine the role of IL-17 in pulmonary eosinophilia during the hypersensitivity response.
References


Romani. 2008. Provision of antifungal immunity and concomitant alloantigen
tolerization by conditioned dendritic cells in experimental hematopoietic

Nikolaev, H. A. Lehr, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, P.
R. Galle, M. Karow, and M. F. Neurath. 2006. Cutting edge: IL-23 cross-
regulates IL-12 production in T cell-dependent experimental colitis. *J
Immunol* 177:2760-2764.

70. Gerosa, F., B. Baldani-Guerra, L. A. Lyakh, G. Batoni, S. Esin, R. T.
Winkler-Pickett, M. R. Consolaro, M. De Marchi, D. Giachino, A. Robbiano,
in human dendritic cells. *The Journal of experimental medicine* 205:1447-
1461.

Eberl, and C. Reis e Sousa. 2008. DC activated via dectin-1 convert Treg into

mediated defense against microbial pathogens. *Annual review of immunology*
26:421-452.

*Current opinion in hematology* 17:53-59.

fates of blood monocytes. *Immunology and cell biology* 87:30-38.


2009. Essential role for neutrophils but not alveolar macrophages at early time
points following Aspergillus fumigatus infection. *The Journal of infectious
diseases* 200:647-656.

77. Svirshchevskaya, E. V., M. A. Shevchenko, D. Huet, F. Femenia, J. P. Latge,
P. Boireau, and N. P. Berkova. 2009. Susceptibility of mice to invasive
aspergillosis correlates with delayed cell influx into the lungs. *International
journal of immunogenetics* 36:289-299.

78. Jaillon, S., G. Peri, Y. Delneste, I. Fremaux, A. Doni, F. Moalli, C. Garlanda,
L. Romani, H. Gascan, S. Bellochio, S. Bozza, M. A. Cassatella, P. Jeannin,
and A. Mantovani. 2007. The humoral pattern recognition receptor PTX3 is
stored in neutrophil granules and localizes in extracellular traps. *The Journal
of experimental medicine* 204:793-804.

Neutrophil extracellular traps capture and kill Candida albicans yeast and
hyphal forms. *Cellular microbiology* 8:668-676.

80. Hazen, S. L., J. P. Gaut, F. F. Hsu, J. R. Crowley, A. d'Avignon, and J. W.
Heinecke. 1997. p-Hydroxyphenylacetaldehyde, the major product of L-
yrosine oxidation by the myeloperoxidase-H2O2-chloride system of


Chapter 2
Methods

**Mice.** Wild-type (C57BL/6J) mice were obtained from the Jackson Laboratories (Bar Harbor, ME). IL-17−/− mice were a generous gift from Kate Eaton at the University of Michigan and have been described previously (1). Mice were housed under pathogen-free conditions in enclosed filter-topped cages. Clean food and water were given *ad libitum*. The mice were handled and maintained using microisolator techniques, with daily veterinarian monitoring. All studies involving mice were approved by the University Committee on Use and Care of Animals at the University of Michigan.

**Aspergillus fumigatus.** Strain ATCC 13073 was grown on Sabouraud dextrose agar (SDA) (Difco) for 14 days. Conidia were harvested by washing plates with sterile phosphate-buffered saline (pH 7.4) with 0.1% Tween 80 (PBS-Tween), followed by filtration of the suspension through two layers of sterile gauze to remove hyphae. Conidia were washed in PBS-Tween, counted with a hemacytometer, diluted to $10^8$ spores/ml in sterile PBS-Tween, and stored at 4°C for up to 4 months.

**Intranasal Challenge.** Mice were injected intraperitoneally with anesthetic (.4 mg/ml Xylazine (Lloyd Laboratories, Shenandoah, IA) + 10 mg/ml ketamine (Fort Dodge, Fort Dodge, IA) in sterile saline (Hospira Inc., Lake Forest, IL)) based on weight. Following
sedation, 20 µl of *Aspergillus fumigatus* suspension was applied intranasally for a total of 2 x 10^6 conidia per mouse per challenge.

**Lung Histology.** Lungs were fixed by inflation with 10% neutral buffered formalin (Sigma). After paraffin embedding, 5-µm sections were cut and stained with hematoxylin and eosin or periodic acid-Schiff (PAS) to detect mucus (McClinchey Histology Lab, Stockbridge, MI).

**Lung Digest for Whole Lung Leukocyte Enrichment.** Lungs from each mouse were excised, washed in PBS, minced, and digested enzymatically for 30 minutes in 15 ml/lung of digestion buffer (RPMI, 5% fetal calf serum, 1 mg/ml collagenase (Boehringer Mannheim Biochemical, Chicago, IL), and 30 µg/ml DNase (Sigma Chemical Co., St. Louis, MO)) as previously described (2). After erythrocyte lysis using NH₄Cl buffer, cells were washed, resuspended in complete media, and centrifuged for 30 minutes at 2000 x g in presence of 20% Percoll (Sigma) to separate leukocytes from cell debris and epithelial cells. Total lung leukocyte numbers were assessed in the presence of trypan blue using a hemocytometer.

**Lymph Nodes.** The draining mediastinal lymph node was excised from the thoracic cavity, placed in 1ml of RPMI (5% fetal calf serum) in a six-well plate (Corning Incorporated, Corning, NY), and ground with the flat edge of a 1ml syringe. The cell suspension was then transferred through a 100 micron screen and washed with 2 ml of RPMI. After erythrocyte lysis using NH₄Cl buffer, cells were washed, resuspended in complete media, and counted with a hemocytometer prior to analysis.
Blood Collection and Serum Separation. Blood was collected by retro-orbital vein bleed at the time of harvest. Serum was collected after centrifugation for 2 min at 6000 rpm in Microtainer tubes (BD Pharmingen). Remaining blood was collected in K2E tubes (BD PharMingen), measured for volume and centrifuged for 10 min at 10,000 RPM. After erythrocyte lysis using NH₄Cl buffer, cells were washed, resuspended in complete media, and counted with a hemocytometer prior to analysis.

Bone Marrow Collection. During harvest, leg shanks were removed from mice and stripped of tissue using a standard razor. Marrow was flushed from femurs and tibias using complete media in a 10cc syringe (BD Pharmingen) tipped with a 25⁵/₈ g needle (BD Pharmingen). Cells were drawn into a 10cc syringe and expressed through a 21g needle to disperse the cells. After erythrocyte lysis using NH₄Cl buffer, cells were washed and resuspended in complete media prior to analysis.

Viable Conidia. Following digestion of the lung, a 100 µl aliquot was taken for analysis. The sample was serially diluted and 10 µl of undiluted, 1:10, and 1:100 diluted digest was plated on SDA media in duplicate. Hyphal foci were counted to determine the number of colony forming units, and the number from each duplicate was averaged to yield a total number of viable conidia per 10 µl of digest per mouse.

Flow Cytometry for Cell Surface Molecules. Cells were washed and resuspended at a concentration of 10⁶ cells/25 µl FA buffer (Difco) + 0.1% NaN₃, Fc receptors were blocked by the addition of unlabeled anti-CD16/32 (Fc block; BD Pharmingen, San
Diego, CA). After Fc receptor blocking, 0.5-1×10^6 cells were stained in a final volume of 50 µl in 96-well round-bottom plates (Corning Incorporated, Corning, NY) for 30 minutes at 4°C. Cells were washed twice with FA buffer, resuspended in 120 µl of 4% formalin (Sigma), and transferred to 12 x 75-mm² polystyrene tubes (Becton Dickinson, Franklin Lakes, NJ). A minimum of 100,000 events were acquired on a FACSCanto flow cytometer (BD PharMingen) using Cell-Quest software (BD Pharmingen). Acquired data was analyzed with FlowJo software (Tree Star, Stanford, CA).

**Flow Cytometric Leukocyte Differential Analysis.** Lymphocytes, neutrophils, and eosinophils were distinguished by virtue of unique combinations of FSC and SSC profiles and CD11c and Gr1 surface expression, as previously described (3). Mature eosinophils were separated from background cells by gating for siglec F^+ forward-scatter^low populations. Non-granulocytic myeloid cells were separated into distinct groups by first gating out eosinophils and leukocytes using forward and side scatter, then removing neutrophils and immature eosinophils by gating out GR1^high CD11c^low cells. The remaining cell populations were then divided into four subgroups for further analysis. Alternatively activated macrophages (AAMΦ) staining consisted of IL-5R and CD206 cross staining (4). Basophils were identified as FSC^low SSC^low Gr1– CD11c– CD3– CD19– CD49b+ FcεRI+ cells as described previously (5). For eosinophil maturation, lung leukocytes were stained and FSC^low SSC^mid-high cells were examined for IL-5R and CCR3 expression. IL-5R^high eosinophils were considered naïve while IL-5R^low eosinophils were considered mature (6). Graphs were made from multiple pooled experiments where n ≥ 6.
**Intracellular Flow Cytometry.** Cells were first stimulated for six hours with PMA (50ng/ml) and Ionomycin (1µg/ml) then stained for CD4 and CD45 (cytokines) or were stained for CD4, CD45, and CD25 (for T_{reg}) without prior stimulation. Cells were first stained for surface markers and washed twice with FA buffer as described above. Cells were then resuspended for 30 minutes in 50 µl of Cytofix/Cytoperm™ (BD PharMingen) for cytokine staining or Fixation/Permeablization solution (eBioscience) for Foxp3 staining. Cells were then washed twice with permeablization solution and stained with fluorescently labeled antibodies for IFN-γ, IL-4, IL-10, IL-17 (BD PharMingen) or Foxp3 (eBioscience). Cells were washed twice more with permeablization solution, resuspended in 125 µl of FA buffer, and transferred to 12 x 75-mm² polystyrene tubes for analysis.

**Morphological Leukocyte Differential Analysis.** Macrophages, neutrophils, lymphocytes, and eosinophils were visualized by standard morphological criteria in Wright-Giemsa-stained samples of lung cell suspensions cytospun onto glass slides (Shandon Cytospin, Pittsburgh, PA). For Wright-Giemsa staining, the slides were fixed for 2 min with a one-step, methanol-based Wright-Giemsa stain (Harleco; EM Diagnostics, Gibbstown, NJ) followed by steps 2 and 3 of the Diff-Quik whole-blood stain kit (Diff-Quik, Baxter Scientific, Miami, FL). A total of 200 to 300 cells were counted from randomly chosen high-power microscope fields for each sample.

**RNA Isolation and cDNA Generation.** Following lung leukocyte enrichment or bone marrow isolation, cells were resuspended in 2 ml of Trizol (Invitrogen). Cells were incubated for 5 min at room temperature then combined with 600µl of chloroform and
shaken for one minute. Following a 3 min incubation at room temperature, samples were spun for 15 min at 13,000 RPM at 4°C and the resultant supernatant transferred to DNAse/RNase free tubes (Corning). Equal volumes of isopropanol were added, and the samples mixed gently prior to a 20 min incubation at RT. Samples were spun for 15 min at 13,000 RPM at 4°C, the supernatant decanted, 1 ml of 80% ethanol added, and spun again for 10 minutes at 13,000 RPM at 4°C. The supernatant was again decanted and the pellet allowed to air dry. 100-600ul DEPC water was added to each pellet depending on the size of the pellet and contains 1ul/ml RNAasin. A primer cocktail (Promega AccessRT kit) was then added to10ul of RNA samples at 0.1ug/ul (total RNA 1ug/reaction) and run on a thermocycler (Applied Biosystems) as per the manufacturers instructions.

**qPCR.** cDNA was mixed with SYBR (Applied Biosystems) and GATA-1 primers (Integrated DNA Technologies) as per the manufacturers instructions. GATA-1 primers: FWD 5’-GCCTGCCATTGGCCCCTTGT-3’ and REV 5’-CCTGTCCTGTCCCTCCGCA-3’. Samples were run on a 7300 Real Time System (Applied Biosystems) and analyzed using 7300 system SDS Software (Applied Biosystems). Quantitation was via 2^-ΔΔCT.

**CD4^+ T Cell Enrichment.** CD4^+ T cells were enriched from splenocyte populations and from combined lung and LDLN populations via magnetic-activated cell sorting (MACS). For MACS, cell suspensions were stained with CD4 (L3T4) Microbeads (Miltenyi Biotec, Auburn, CA) and enriched via positive selection on a MidiMACS separator (Miltenyi Biotec). Enriched populations were >85% pure as assessed by flow cytometry.
Adoptive Transfer. Enriched CD4\(^+\) T cells were suspended in PBS at 0.8-1×10\(^7\)/ml and 1ml of cell suspension was adoptively transferred to naïve recipient mice via lateral tail vein injection.

Statistical Analyses. All values are reported as mean ± standard error of the mean unless otherwise noted. 3-6 independent experiments were pooled to generate the mean unless otherwise noted. Differences between two groups were evaluated with a two-tailed Student’s \(t\) test; \(p<0.05\) were considered statistically significant. Correlation between cell types and conidia clearance was determined using Ordinary Least Squares Regression analysis. Slope, y-intercept, \(R^2\) value, and \(p\)-value were determined for each data set. \(p<0.05\) were considered statistically significant.
References


Chapter 3
Characterizing the Hypersensitivity Response

Introduction

*Aspergillus fumigatus* is a common mold and the focus of extensive research due to its ubiquitous nature. *A. fumigatus* disseminates via conidia – hydrophobic spores – which bud off fungal hyphae and are distribute through the air. Once the conidia reach a warm, moist environment such as the lungs, they lose their hydrophobic properties and begin to germinate (1). Following conidial swelling and germ tube extension, the fungus develops invasive hyphae (2) and the cycle repeats itself.

Conidia are readily and frequently inhaled into airways at a rate of several thousand a day (3), and pulmonary exposure to large doses is not uncommon (4). Though *A. fumigatus* can pose a serious threat to immunocompromised individuals, even relatively large doses of conidia pose little danger to immunocompetent hosts as the immune system is capable of clearing conidia from the lungs before the fungus can take hold. The immune response to inhaled *Aspergillus fumigatus* is characterized by a complex interaction between the innate and adaptive immune response, both of which are quickly activated by the presence of fungi (5, 6). Macrophages and neutrophils efficiently neutralize low doses of germinating conidia in the lung (7, 8), and resting conidia are cleared from the lung by macrophages without the induction of an inflammatory response (9, 10). However, exposure to large numbers of viable conidia results in a complex collection of cell types, pathways, and cytokines in response to the fungus. Macrophages
(11), neutrophils (12), dendritic cells (13), monocytes (14), eosinophils (15), and natural killer cells (16) all play a role in host defense, as do aspects of the complement system (17).

No less important is the adaptive immune response. The Th1 adaptive immune response is important in defense against invasive *A. fumigatus*, with progressive invasion of infected tissue associated with decreased IFN-γ production and poor T cell proliferation in individuals with compromised immune systems (18). In addition, inhibition of IFN-γ or TNF-α enhances fungal invasion (19, 20). The Th1 response is the primary reaction to large doses of inhaled conidia: following a thirty second inhalation of aerosolized *Af* spores, the Th1 response in mice peaks one week after initial infection resulting in the expression of TNF-α, IFN-γ, IL-12, and IL-18 (21).

Chronic exposure to *A. fumigatus* conidia is common but little is known about the host response under such conditions. Much of the host response literature for *A. fumigatus* has focused on the response to acute conidia exposure, usually in immunocompromised animals, due to the clinical impact of invasive aspergillosis. Other studies have examined the hypersensitivity response to conidia or *Aspergillus* antigen extracts in mice previously sensitized systemically to *Aspergillus* (22-24). Our laboratory has previously reported that two intranasal exposures to *A. fumigatus* conidia without a sensitizing event do not result in an adaptive immune response (25, 26). However, repeated pulmonary exposure to *A. fumigatus* conidia results in a strong Th2-mediated hypersensitivity response consisting of eosinophilia, mucus hyper-secretion, IgE secretion, and cytokine production (27).

Our initial objective was to determine if additional challenges – four challenges and eight challenges – would stimulate an adaptive response and, if so, analyze the
development of the response in the lungs, including pulmonary inflammation, CD4 T cell polarization and conidial clearance. Here we show that the reaction to repeated pulmonary exposure is a dynamic adaptive immune response characterized not only by a T\textsubscript{H}2 hypersensitivity response, but early regulatory T cell activity and a mounting T\textsubscript{H}17 reaction. Moreover, repeated exposure does not result in increased mortality, and hypersensitivity does not significantly enhance clearance of \textit{A. fumigatus} from the lung.

**Aims**

1. Determine the cellular composition during acute and chronic \textit{Af} conidia-driven inflammation
2. Determine the adaptive response to chronic pulmonary exposure to \textit{Af} conidia
3. Determine whether hypersensitivity hinders the immune system’s capacity to clear conidia from the lungs

**Results**

**Chronic pulmonary exposure to \textit{Aspergillus fumigatus} conidia results in pulmonary inflammation.**

To determine the host response to chronic \textit{Af} conidia challenge, mice were challenged with zero, two, four, or eight weekly inoculums of 2 x 10\textsuperscript{6} live \textit{Aspergillus fumigatus} conidia and harvested 24 hours after final challenge. The survival rate over the course of 8 weeks was 100% (Fig. 3-1A). Lungs of challenged mice were excised, minced, and digested to quantify both the pulmonary inflammatory response and levels of viable conidia. Small aliquots were plated on SDA in a ten fold dilution series and mold colonies counted. We found that 24 hours after intranasal challenge low numbers of
viable conidia could still be detected in the lung (approximately 1%, Fig. 1B) and potentially serve as a source of continued antigen or inflammatory stimulus. Two challenges stimulated the influx of a small number of leukocytes into the lungs, the most numerous of which were neutrophils (Fig. 3-3B). Repeated challenges gradually augmented pulmonary inflammation but did not significantly alter the efficacy of clearance, as mice exposed eight times to conidia still had levels in the lungs similar to those that had been challenged two or four times with conidia (Figs. 3-3A & 3-1, respectively). Repeated challenge also caused an expansion of the lymphocyte populations in the draining lymph node (mediastinal lymph node), most notably between the second and fourth challenge (Fig. 3-3A). Thus, chronic exposure promoted development of an inflammatory response but did not enhance or impede conidial clearance.

We next examined the composition of the inflammatory response during chronic Af exposure. Whole lungs from mice challenged zero, two, four, and eight times were examined histologically in H&E and PAS stained sections. Following two challenges, granulocytic infiltrates were evident around the airways, with minimal changes in goblet cells (PAS+, Fig. 3-2A). After four challenges, the inflammatory infiltrate had markedly increased, including large numbers of eosinophils, and goblet cell metaplasia was evident (as indicated by large numbers of PAS+ cells in the airway epithelium). In addition, at this time point, there were a large number of multinucleated giant cells in the leukocyte infiltrates (Fig. 3-2B). By eight challenges, the inflammatory response had decreased, including fewer multinucleated giant and metaplastic goblet cells. Thus, chronic exposure to Af conidia induced an increasingly stronger pulmonary inflammatory response through
four conidia challenges that leveled off or began to resolve even in the face of continued *Af* challenges.

To further analyze the kinetics of the pulmonary inflammatory response, leukocytes were isolated from enzymatically dispersed lungs of challenged mice. Consistent with our histological analysis, we observed a significant difference between the number of cells found in untreated mice and those challenged twice (Fig. 3-3A). The influx of cells in the lung was almost exclusively granulocytes (Fig. 3-3B), indicative of primarily an innate response. However, mice challenged four times with conidia had a six fold increase in the number of recruited leukocytes in the lungs compared to two challenges. The inflammatory infiltrate was comprised of various myeloid cells and lymphocytes, with eosinophils being the dominant cell type. CD4 numbers did not increase significantly following two challenges, but four challenges yielded a five-fold increase in the total number of CD4 T cells (Fig. 3-3B). There was a similar influx of B cells into the lungs; however, CD8 T cell numbers remained relatively low. After eight challenges, the total number of myeloid cells was lower while CD4 T and B cells remained elevated. In the draining lymph nodes, there was an expansion of the CD4 T and B cell populations between two and four challenges that persisted through eight challenges (Fig. 3-3B). Thus, the influx of eosinophils, together with increased numbers of CD4 T cells and B cells in the lungs and mediastinal nodes, suggested the potential development of a Th2 response to *Af* conidia challenge during repeated exposure that wanes as the number of exposures continues.

**Precursor cells, macrophages, and dendritic cell populations expand in response to conidia challenge.**
Our next objective was to analyze the kinetics of the non-granulocyte myeloid populations during chronic Af conidia exposure. This heterogeneous population includes antigen-presenting cells, effector cells and regulatory myeloid cells. CD45+ cells isolated from the lung were stained with anti-Gr1 and anti-CD11c, and lymphocytes and mature eosinophils were removed from the cell pool by excluding cells with a low side-scatter profile (Fig. 3-4A). Cells expressing high levels of Gr1 but low levels of CD11c were gated out to remove neutrophils and immature eosinophils. The remaining cell population clustered into four distinct subpopulations, which we called Groups I-IV (Fig. A2-2).

Each of these subpopulations was analyzed for expression of CD16/32, Ly6C, CD80, as well as its autofluorescence and forward scatter/side scatter profile. CD16/32 (FcR) expression was found on all groups, indicating all groups are of myeloid lineage. Ly6C, a marker of late myeloid precursors, was highest in Group III. This, along with the large size-distribution of the subpopulation and lack of autofluorescence indicated differentiating precursor cells (Fig. 3-4B). Likewise, the lack of Ly6C expression, high autofluorescence, and expression of CD80 – a marker of maturity – indicated that Group II was composed of macrophages. Group I was composed of dendritic cells, as supported by the CD80 expression, lack of autofluorescence, and moderate Ly6C expression. We could not specifically define Group IV by cell sub-type, only by surface phenotype. Group IV cells expressed relatively high levels of Ly6C, expressed no CD80 and were moderately autofluorescent. These cells are most likely macrophage precursors based on their scatter profile as well as their moderate autofluorescence. None of the populations contained alternatively activated macrophages: all stained negative for IL-5Rα and CD206 (Fig. 3-5). Likewise, all of the subgroups stained negative for pan NK markers.
There was a nearly five-fold increase in dendritic cell (Group I) numbers between two challenges and four challenges, with total numbers dropping significantly by eight challenges (Fig. 3-6). Group III numbers showed a similar pattern, while macrophage (Group II) numbers doubled between two and four challenges and stayed high over the course of exposure. Levels of Group IV cells remained unchanged over time. Following exposure to conidia, the dendritic cells increased expression of CD11b, indicating that new cells were coming in to the lung (28). Similarly, the macrophage population had increased CD11b and decreased siglec F expression over time, again indicating an influx of new cells. Group IV non-granulocytic myeloid cells (NGMC), whose numbers did not change over time, increased CD11b expression concurrent with the development of peak inflammation. This reinforces the idea that Group IV is composed of precursor cells transitioning into a more mature cell type. Since the ‘newness’ of the cell population changes but total levels remain the same, the Group IV is likely a transitory population for monocytes on their way to becoming more mature myeloid cells.

**Chronic Af challenges result in an influx of antigen presenting cells into the lungs.**

The numbers of antigen presenting cells frequently increases during inflammation, so we wished to see if this was true in our model. The generation of Th2 responses has recently been linked to basophils (29), so we asked whether the number of basophils in the lungs increased concomitant with the development of the Th2 response. Basophils were identified using antibodies against CD49b and FcεRI as described previously (30) (Fig. 3-7A). Consistent with their potential role in the development of the Th2 component of the response to *Af* conidia, the numbers of basophils in the lungs increased at two challenges (prior to the appearance of IL-4+ CD4 T cells, Fig. 3-7B) and
continued to increase between two and four challenges, the period when the Th2 response fully developed.

**CD4 T cells in the lung and lymph nodes show different activation and function after two, four, and eight challenges.**

T cells are essential to inflammatory response resulting from four intranasal challenges; depletion of CD4 T cells completely abrogates hypersensitivity and eosinophil influx (27). We wished to determine whether repeated exposure resulted in CD4 T cell activation. CD4 T cells were identified in both the lung and lymph node by CD45 and CD4 staining. Cells were additionally stained with fluorescently labeled antibodies specific for CD44 and CD69, both of which are markers of T cell activation. CD4 T cells that were CD44\(^{\text{high}}\) and CD69\(^{+}\) were counted as activated. In the lung, just two exposures to conidia resulted in an increase in the percentage of CD4 T cells that were activated (Fig. 3-8A). The percentage of activated CD4 T cells did not significantly increase between two and four challenges, but the increase in total numbers of activated cells was significant (Fig. 3-8B). Between the four-challenge and eight-challenge time points the percentage and total number of activated CD4 T cells increased slightly but not significantly, supporting the idea of a sustained adaptive immune response over the course of exposure. In the lymph node, the percentage of activated T cells remains constant throughout the course of exposure. This is consistent with previous reports that have found that CD4 T cells activate in the lungs but not the lymph nodes in response to fungi (31). Therefore, pulmonary exposure to *A. fumigatus* results in T cell activation in the lungs but not the lymph node. However, it is unlikely that activation alone results in
hypersensitivity as CD4 T cell activation can be observed after two challenges when there is no hypersensitivity response.

To determine whether a lack of regulatory cells is responsible for hypersensitivity we determined the percentage of T\textsubscript{REG} within the pool of CD4 T cells. Similarly to T cell activation, the percentage of CD4 T cells with a regulatory phenotype (CD25\textsuperscript{+} Foxp3\textsuperscript{+}) was constant in the lung-associated lymph nodes but dynamic in the lungs. In the lungs, the percentage of cells expressing a T\textsubscript{REG} phenotype increases significantly in mice challenged twice and then receded during hypersensitivity (Fig. 3-9). The sudden increase in regulatory T cells during the initial exposure may explain the relative lack of an inflammatory response seen after two challenges. Interestingly, the total number of CD4 T cells does not increase significantly in mice challenged twice versus untreated mice, while the percentage of T\textsubscript{REG} in the lung increases nearly 50%. This indicates that the small number of CD4 T cells entering the lungs during the first two challenges (Fig. 3-9) are almost exclusively T\textsubscript{REG} or that some of the endogenous T cells in the lungs are being converted to regulatory function in response to low doses of A. fumigatus conidia. Thus, the initial exposure to the fungus induces tolerance rather than inflammation, but this response is eventually replaced by an aggressive inflammatory reaction. Though the total number of regulatory T cells increases during hypersensitivity as has been reported previously (32), the Effector:Treg ratio begins to grow as expansion of the effector T cell pool outpaces that of regulatory T cells.

These observations logically led us to examine the cytokine production over the course of exposure. We examined CD4 T cells cytokine production by flow cytometry to determine which cytokines were being expressed during each phase of the response.
During the initial response to conidia challenge there is a burst of IL-10 production, supporting the conclusion that early inoculums of *A. fumigatus* drive tolerance (Fig. 3-10A). Predictably, production of IL-4 spikes after four challenges when there is acute hypersensitivity and a significant influx of eosinophils, and there is a corresponding drop in the percentage of IL-10-producing CD4 T cells. However, we were surprised by the relative lack of change in IFN-γ production at all time points as well as the significant increase in IL-17 production that accompanied hypersensitivity. While the total number of IFN-γ producing cells did increase, the percentage expressing the cytokine stayed almost constant through four challenges. It is not until 8 challenges that a significant increase in the percentage of CD4 T cells expressing IFN-γ is seen. In sharp contrast to this, there is constant increase in the percentage of CD4 T cells expressing IL-17 over the course of exposure, and between two challenges and four challenges there is a ten-fold jump in the number of these cells (Fig. 3-10A). Production of IL-17 is high after four challenges and remains high at the late time point suggesting that IL-17 and the Th17 response may play a role in driving chronic inflammation. This is reinforced by the presence of IFN-γ/IL-17 double-producing CD4 T cells. While the number of IFN-γ/IL-10 and IL-10/IL-17 producers rises slightly with multiple challenges, there is a striking and significant increase in the number of IFN-γ/IL-17 producers between two and four challenges (Fig. 3-10B). IFN-γ/IL-17 double-positive CD4 T cells are associated with inflammation in a number of autoimmune models (33-35), and their presence suggests a role for IL-17 in maintaining an inflammatory response to *A. fumigatus*.

**Precursor levels are associated with decreased fungal clearance during the hypersensitivity response.**
When measuring the number of viable conidia in the lung, we noticed that the number measured in each lung following four challenges was highly variable. While other time points had relatively tight clustering of data points, the counts following four challenges varied from no detectable conidia to $1.5 \times 10^5$ viable spores. Given the wide distribution of still-viable conidia, we wondered if there was a positive correlation between a lack of fungal clearance and a particular cell type. We therefore generated an XY scatter plot for each cell type showing both the number of conidia detectable in each lung versus the number of that cell. Each mouse is represented as a single point within the graph. Regression analysis was then used to determine whether there was a positive or negative correlation between each cell type and the number of detectable conidia and whether that correlation was significant (Fig. 3-11).

Most cell types showed little correlation with a lack of clearance. Neutrophil, dendritic cell, macrophage, and CD4 T cell numbers had virtually no relation to the number of conidia that could be isolated from the lung, while CD8 T cells and B cells showed a negative correlation that did not quite reach statistical significance. Similarly, there was a modest correlation between conidia and eosinophils that also did not reach statistical significance ($p = .063$). However, there was a strong correlation between Group III myeloid precursors and fungal levels ($p = .036$), which is unsurprising given the central role of monocytes in the CD4 T cell response during fungal infection (14). Most surprising though was Group IV, which maintained a relatively constant number of cells over the course of exposure (Fig. 3-11) and had an extremely high correlation with the number of viable conidia ($p = .002$). Like the number of conidia, the number of Group IV cells varied dramatically at the four challenge time point. It is unclear though if the correlation is causative. It is plausible that a cell population would be increased in
response to lingering conidia rather than being the source of poor clearance. However, these data do indicate which cell types are most likely playing a central role – either positive or negative – in defense and clearance.
Figure 3-1. Conidia introduced via weekly intranasal challenge do not induce death and can be detected twenty-four hours after exposure. (A) Mice were challenged intranasally with $2 \times 10^6$ live conidia once a week for eight weeks. Shown is the survival of all mice in the cohort over the course of eight weeks. (B) Following digestion of the lungs and aliquot of digest was serially diluted and plated on SDA media and hyphal foci were counted. The graph shows the average viable conidia per lung detected 24 hours after zero, two, four, and eight challenges. Starred bars indicate $p < .05$. 
Figure 3-2. **Hypersensitivity in the lung is accompanied by cellular infiltrate around the airways and mucus hyper-secretion.** Lungs from mice challenged zero, two, four, or eight times were fixed in formalin and embedded in paraffin blocks. Histological slices were then stained with H&E or PAS. **(A)** Slides were examined at 40X magnification. Arrows indicate eosinophil and neutrophil infiltrate. In PAS staining, bright purple cells indicate mucus secretion. **(B)** In mice challenged four times with conidia, multinucleated macrophages were observed in the lungs.
Figure 3-3. Repeated intranasal exposure to *Aspergillus fumigatus* conidia generates a hypersensitivity response in C57BL/6 mice. (A) Total cells in both lungs and lymph node was calculated by counting total live cells in both tissue types using trypan exclusion and multiplying by the percentage of cells that were CD45⁺. (B) Cell populations were identified as described in Figure A-1. The non-granulocytic myeloid cell (NGMC) population consists of the total numbers pooled from Groups I, II, III, and IV. All bars represent the average of at least four separate experiments.
Figure 3-4. **Subsets of myeloid cells within the lung have distinct expression patterns of cell surface markers.** (A) Live cells from the lung were stained with a spectrum of fluorescently labeled antibodies and analyzed using FLOW cytometry. CD45\(^+\) cells were first gated, and forward-scatter/side-scatter analysis was used to separate myeloid cells from lymphocytes (FSC\(^{\text{low}}\) SSC\(^{\text{low}}\)) and eosinophils (FSC\(^{\text{low}}\) SSC\(^{\text{mid-high}}\)). Neutrophils (CD11c\(^{\text{low}}\) GR1\(^{\text{high}}\)) were then removed. The remaining cell population clusters into four distinct subpopulations labeled as Group I, II, III, and IV. (B) Subpopulations were identified by examining FSC/SSC profile, surface marker expression, and autofluorescence. Black lines indicate expression; gray peaks indicate IgG controls.
Figure 3-5. Subpopulations do not consist of alternatively activated macrophages or natural killer cells. Each subpopulation was examined for expression of IL-5Rα and CD206 or expression of pan NK surface markers. Black lines indicate expression; gray peaks indicate IgG controls.
Figure 3-6. New cells are recruited to the lung during peak inflammation. Each subpopulation was analyzed for total cell number after each challenge as well as expression of CD11b, MHCII, and siglec F at each time point (Untreated = gray background, 2 Challenges = gray dashed line, 4 Challenges = black dashed line, 8 Challenges = solid black line).
Fig. 3-7. Basophil numbers significantly increase during the hypersensitivity response. (A) Basophils were identified by gating for FSC$^{low}$ SSC$^{low}$ Gr1$^{-}$ CD11c$^{-}$ cells, then gating out T cells and B cells (CD3$^{+}$ and CD19$^{+}$ cells). The remaining cells that were CD49b$^{+}$ FcεRI$^{+}$ were classified as basophils. (B) The mean number of basophils following zero, two, four, and eight challenges is shown. Starred bars indicate p < .05.
Figure 3-8. CD4 T cells are activated in response to *A. fumigatus* conidia in the lung but not the lymph node. (A) Lung cells were stained antibodies for CD45, CD4, CD44, and CD69. CD4 T cells were isolated via gating and those that were CD44$^\text{High}$ CD69$^+$ (FLOW gate) were counted as activated. Each time point is a representative concatenation of three samples. (B) Both the percentage and total number of activated CD4 T cells in the lung and lymph nodes was calculated for each mouse and averaged for each time point. n ≥ 6 for each time point.
Fig. 3-9. The percentage of CD4 T cells displaying a regulatory phenotype increases during the early immune response, but total numbers increase over the course of exposure. Cells taken from both lung and mediastinal lymph node were stained for CD45, CD4, and CD25. Following permeabilization cells were then stained for intracellular Foxp3 expression. Effector:Treg ratio was determined by comparing the percentage of CD4 T cells that were double-positive for CD25 and Foxp3 to those that were double-negative. Bars represent the mean of each mouse at each time point. n ≥ 6 for each time point.
Figure 3-10. Each stage of the immune response to *A. fumigatus* displays a distinct CD4 cytokine profile in the lung. (A) Cells taken from lung were stimulated for six hours with PMA and Ionomycin and then stained with fluorescently labeled antibodies specific for CD45 and CD4. Following permeabilization cells were then stained for intracellular IFN-α, IL-4, IL-10, and IL-17 expression. The mean percentage and mean total number of CD4 T cells expressing each cytokine is shown. (B) The mean number of CD4 T cells expressing multiple cytokines is shown. n ≥ 6 for each time point.
Figure 3-11. Poor clearance of conidia is positively associated with specific cell populations during peak inflammation. Following 4 conidia challenges, the number of viable conidia per mouse was compared to individual cell populations in each lung. Each point represents the number of viable conidia vs. the number of cells in an individual mouse. Slope, y-intercept, $R^2$ value, and $p$-value were determined using regression analysis.
Figure 3-12. Repeated exposure to low levels of pulmonary exposure conidia results in hypersensitivity and a dynamic immune response. The rise and fall of the four main branches of the adaptive immune response as well as various cell populations is shown. Both graphs are in arbitrary units.
Discussion

We have demonstrated in this study that chronic exposure of an immunologically intact host to *Af* conidia does not result in invasive aspergillosis or fatal disease but does result in the development of chronic pulmonary inflammation and a CD4 T cell response that is dynamic in its polarization, switching from an innate response and high regulatory:effector CD4 T cell ratio to a low regulatory:effector ratio and an adaptive response that shifts in its ratio of $T_H1:T_H2:T_H17$ cells as the number of conidia challenges increases (Fig. 3-12). However, it should be noted that all three types of CD4 T cell responses are present in the lungs at some level at four and eight challenges. While the number of IFN-$\gamma$/IL-10 and IL-10/IL-17 producing CD4 T cells rises slightly with multiple challenges, there is a striking increase in the number of IFN-$\gamma$/IL-17 producing CD4 T cells between two and four challenges (Fig. 3-10B). IFN-$\gamma$/IL-17 double-positive T cells are associated with inflammation in several models of autoimmunity and graft rejection (33-36) and their presence suggests a role for IL-17 in maintaining the inflammatory response to *A. fumigatus*.

Viable conidia could be detected 24 hrs after introduction following each challenge, providing a sustained and repeating source of antigen or inflammatory stimuli during the evolving CD4 T cell response. Neutrophils, a major cell type during the early phases of the response, are well-known to play a central role in host defense against *Aspergillus* (12, 37-40) and were seen at all stages of the response, particularly early stages prior to engagement of the adaptive response. Eosinophils, the dominant cell type during hypersensitivity, have been repeatedly found in $T_H2$ responses. The chronic inflammatory response included the recruitment of antigen-presenting cells such as
basophils, dendritic cells, macrophages, CD4 T cells, and B cells, all of which are capable of driving T\textsubscript{H}2, T\textsubscript{H}1, T\textsubscript{H}17 and T\textsubscript{reg} responses. In addition, exposure to \textit{A. fumigatus} conidia or fungal glucan can induce regulatory responses via TLR2 and dectin-1 (41, 42). This then raises an interesting question: why is there a marked transition from tolerance and mild inflammation to induction of T\textsubscript{H}2, T\textsubscript{H}1 and T\textsubscript{H}17 responses?

Expansion of the regulatory T cell population is important for limiting disease because T\textsubscript{reg} cells ultimately aid in the clearance of fungi by limiting Th1 inflammation (43) or dampening T\textsubscript{H}2 hypersensitivity reactions (44, 45). In aspergillosis studies using high doses of conidia (10\textsuperscript{8} spores per mouse) there is a strong T\textsubscript{H}1 response that occurs one week after the initial exposure (46) rather than the T\textsubscript{H}2 and T\textsubscript{H}1/T\textsubscript{H}17 responses that we have reported here during chronic \textit{Af} conidia exposure.

There are several possible explanations then for the transition from tolerance to hypersensitivity that we observed during chronic \textit{Af} conidia exposure. One possibility is that the accumulation of innate cells eventually overwhelms the regulatory response. Chitin – which is generated following conidial germination – can drive an accumulation of innate cells, stimulating inflammation and ultimately leading to an allergic response (47). We show here that viable conidia are still present twenty-four hours after challenge, and we have previously shown that germinating fungi can be detected in the lungs even when low concentrations of conidia are used. Thus, it is possible that chitin production results in an innate response that outpaces the tolerance response and eventually results in the engagement of T\textsubscript{H}2 adaptive immunity. Another possibility is that control of the T\textsubscript{H}1 response is what ultimately drives the development of the T\textsubscript{H}2 response. The T\textsubscript{H}1 response has repeatedly been shown to cause tissue damage (48), so it is reasonable to suspect that the immune system would dampen the T\textsubscript{H}1 response to a dose of conidia that
can easily be cleared by the innate immune system. Such T_{H1} suppression could in turn allow the expansion of a T_{H2} response in reaction to multiple challenges, as T_{H1} and T_{H2} responses are often reciprocally regulated. Moreover, T_{H1} and T_{H17} are also reciprocally regulated (49) which could explain the increased number of IL-17 producing CD4 T cells.

Similar to the development of the T_{H2} response, the T_{H17} adaptive immune response during chronic *Af* conidia exposure may be a result of a combination of factors. The initial T_{H17} adaptive immune response may be triggered simply by the presence of conidia. Like regulatory T cells, T_{H17} is promoted by fungal cell wall components via dectin-1 (50, 51). In addition, T_{reg} can facilitate the differentiation of T_{H17} cells (52, 53), and regulatory T cells themselves can be converted to T_{H17} cells (54), a process that is facilitated by DC (55). Moreover, IL-10 inhibits production of IFN-γ but not IL-17 (56). Thus, the initial T_{H17} response seen following two challenges may be driven by regulatory T cell conversion to T_{H17}. This process would be aided by the dampened T_{H1} response, as the development of T_{H17} cells is inhibited by T_{H1} and T_{H2} cytokines. On the other hand, CD4 T cells already committed to the T_{H17} lineage are resistant to T_{H1}- or T_{H2}-mediated suppression (57) which could explain why we observed that IL-17 producing CD4 T cells continue to expand even during the T_{H2}-driven inflammatory response that follows four challenges.

The T_{H17} T cells in our study are also likely playing an active role in shaping the reaction to conidia. Not only does the T_{H17} arm of the adaptive response regulate T_{H1} differentiation (58, 59), but it can dampen production of indoleamine-2,3-dioxygenase (IDO) which enhances fungal clearance by inhibiting inflammation. This could explain why after eight challenges the adaptive response is still not capable of efficiently clearing
conidia (60). There have been no reports to our knowledge suggesting that the T\textsubscript{H}17 response regulates T\textsubscript{H}2 responses, so the presence of T\textsubscript{H}17 does not explain the dampening of the hypersensitivity response between four and eight challenges. In contrast, previous studies have indicated that T\textsubscript{H}2 airway inflammation is enhanced by T\textsubscript{H}17 (61). How then, does the T\textsubscript{H}17 response ultimately replace the T\textsubscript{H}2 reaction seen earlier during chronic \textit{Af} conidia exposure? Rather than suppressing T\textsubscript{H}2, it may be that T\textsubscript{H}17 becomes the dominant adaptive response through attrition. Repeated exposure to an antigen leads to restimulation-induced cell death of CD4 T cells, but it has been reported that in autoimmune disease models T\textsubscript{H}17 cells are resistant to this form of apoptosis (62).

Thus, the emergent T\textsubscript{H}17 response may arise as an imperfect immune compromise when dealing with low levels of repeated conidia. While a T\textsubscript{H}2 response does little to aid in the clearance of non-hyphal \textit{A. fumigatus} and hinders function of the lungs, a persistent T\textsubscript{H}1 response could result in severe damage to the tissue. T\textsubscript{H}17 hinders T\textsubscript{H}1-mediated clearance of fungi (60), but on its own the T\textsubscript{H}17 response has anti-fungal properties (63-66). Therefore it is quite possible that repeated pulmonary exposure to \textit{Af} conidia eventually leads to an immune homeostasis where the ultimate response creates the least damage while still controlling microbial load (conidia germination).
References


Chapter 4
The Role of IL-17 in Hypersensitivity

Introduction

In the previous chapter we showed that repeated pulmonary exposure to *Aspergillus fumigatus* conidia led C57BL/6 mice to develop pulmonary hypersensitivity with increased production of IL-17 over the course of infection. IL-17 and the Th17 response have an unclear relationship with allergy and hypersensitivity, and given the robust IL-17 response seen in mice challenged multiple times we wished to elucidate the relationship between IL-17 and hypersensitivity response to *Aspergillus fumigatus* conidia. To do this we used an identical challenge protocol to the one used in Chapter 3, only in addition to wild-type mice we used a previously characterized IL-17 knockout strain on a C57BL/6 background (1).

IL-17 was discovered over fifteen years ago (2), but it was not until 2005 that the scientific community realized that it is part of an adaptive response wholly separate from the classic Th1 and Th2 branches previously characterized (3, 4). Until that time researchers had labored under the belief that the Th1 and Th2 responses balanced one another and constituted the sum total of the adaptive response (5). Which of these two branches was dominant depended on the pathogen of interest: Th1 dealt with intracellular pathogens (6), and Th2 dealt with extracellular pathogens (7). However, with the discovery of Th17 it became clear that old paradigm was obsolete, and new research has endeavored to determine the role of Th17 in the newly emerging model.
The role of the Th17 response has been viewed in a number of ways. It is sometimes seen as a bridge between innate and adaptive immunity (8, 9), as a protective mechanism for mucosal surfaces (10, 11), and as the source of many chronic inflammatory diseases once thought to be mediated by the Th1 response (12). Of particular interest is the emerging role of Th17 in diseases that were once thought to be mediated by the Th2 adaptive response. Th17 and IL-17 have been shown in numerous studies to play a significant role – both positive and negative – in both airway hypersensitivity as well as fungal disease.

In response to fungus and other pathogens, Th17’s role is highly varied, as Th17 cytokines have been repeatedly shown to possess a wide variety of anti-microbial activity. IL-17 and IL-22 have been shown to work together to enhance the expression of anti-microbial peptides (13-15), and IL-17 and IFN-γ together can induce the production of defensins in humans (16). IL-17 is necessary for defense against systemic candidiasis (17) and has been previously shown to have a variety of anti-fungal properties (18-21). Unfortunately, the Th17 response tends to be inferior to Th1 when it comes to fungal defense and can hamper the Th1 response (21). It has even been speculated that microbes such as fungi – which promote Th17 differentiation via dectin-1 signaling – may preferentially activate the Th17 response over Th1 as a form of immune evasion (22).

The involvement of Th17 in hypersensitivity appears to be a double-edged sword as well. IL-17 is increased in human asthma (23), and IL-17 levels correlate with the severity of asthma as well as other allergies (24, 25). Moreover, IL-17 has been shown to directly affect neutrophil recruitment during OVA-induced asthma in mice (26). However, it has also been shown that IL-17 can be a negative regulator of asthma in mice (27), and IL-17 depletion can exacerbate eosinophilia in lungs (26). Based on these
observations, the role of IL-17 in airway hypersensitivity seems to be time-dependent. At some stages of inflammation T\textsubscript{H}17 is a detriment and at others it is a benefit. This concept meshes nicely with the dynamic cytokine response we demonstrated in the last chapter, and as such, we wished to see what effect a lack of IL-17 production would have on the hypersensitivity response.

**Aims**

1. Determine if IL-17 drives accumulation of leukocytes in the lung during hypersensitivity
2. Determine if IL-17 alters the adaptive immune response to \textit{Af}
3. Determine if IL-17 inhibits clearance of conidia from the lung

**Results**

	extbf{IL-17 exacerbates hypersensitivity but is not responsible for mucus hyper-secretion.}

IL-17 has shown to be a hindrance to fungal clearance, but it has also been shown to be essential to defense against several pathogens. More importantly, the T\textsubscript{H}17 response has been shown to play a minor role in fungal defense under some circumstances. To see whether a lack of IL-17 increased the mortality rate of C57BL/6 mice, mice that were to be challenged eight times were checked daily for fatalities. Over the course of five separate runs of at least three mice, not a single death in either the wild-type or IL-17 knockout mice was observed (Fig. 4-1). Moreover, there were no signs of mouse morbidity (data not shown).

Using flow cytometry, cell populations were identified using a battery of fluorescently labeled antibodies specific for cell surface markers as previously described.
in Chapter 3. In the lung, there was no significant difference in the total leukocyte number following zero, two, and eight challenges in wild-type and IL-17\(^{-/-}\) mice (Figure 4-2A). However, there was a thirty-three percent reduction in the total leukocyte number in IL-17\(^{-/-}\) mice following four challenges. The extra cells present at this time point consisted of neutrophils, eosinophils, macrophages, dendritic cells, CD4 T cells, and B cells (Fig. 4-2B). There was no difference between CD8 T cells nor, surprisingly, myeloid precursors at this time point (Group III). Interestingly, the only population that showed a significant difference after eight challenges was the macrophage populations, which remains high over the course of exposure in wild-type mice. Conversely, more differences were observed in the lymph node following eight challenges as opposed to four. Though there was a significant difference in total lymphocyte number between wild-type and IL-17\(^{-/-}\) mice following four challenges, the difference in cell number was due entirely to an expansion of the B cell population (Figure 4-2B). In contrast, there are significantly fewer CD4 T cells present in the mediastinal lymph node of IL-17\(^{-/-}\) mice following eight challenges along with fewer B cells and CD8 T cells.

Basophils have been recently shown to play a central role in driving the T\(_{h2}\) response (28). We wished to compare the levels in WT and IL-17\(^{-/-}\) mice to determine if altered basophil levels accounted for the disparity in cell numbers seen during peak inflammation. To our surprise, basophil levels were nearly identical in the WT and IL-17\(^{-/-}\) strains at every time point (Fig. 4-3).

H & E staining confirmed what flow cytometry had already told us, namely that lack of IL-17 attenuates cellular infiltration into the lungs. Cellular infiltrate could still be observed around the airways, particularly after four challenges, but the intensity of cellular infiltrate was greatly reduced in mice lacking IL-17 (Fig. 4-4A). Interestingly,
PAS staining revealed that IL-17<sup>−/−</sup> mice still showed mucus hyper-secretion in the airways, though its prevalence and intensity were slightly reduced (data not shown). Likewise, the lungs of IL-17<sup>−/−</sup> mice also contained multi-nucleated macrophages, though again, they were less frequent than in their wild-type counterparts (Fig. 4-4B). Finally, as a simple visual confirmation of our observations, we stained leukocytes from digested lung with a Wright-Giemsa stain and compared cellular composition. As seen with FLOW cytometry, both mouse strains contained similar ratios of cell types, though WT mice had a higher percentage of eosinophils during the hypersensitivity response following four challenges (Fig. 4-5).

**IL-17 does not drive T cell activation or production of IL-4, but may play a role in the regulatory response.**

Given the central role of CD4 T cells in hypersensitivity, we wished to see whether a lack of IL-17 production affected CD4 T cell activation or the presence of regulatory T cells in either lung or mediastinal lymph node. We found that there was no significant difference in percentage of CD4 T cell activation following four challenges in either the lung or lymph node (Figure 4-6A). There was a small but significant difference in the lungs following eight challenges, but at no time point in the lymph node was the difference significant. In contrast, there was a significant difference in the percentage of CD4 T cells expressing the CD25<sup>+</sup> Foxp3<sup>+</sup> regulatory phenotype in the lungs during the initial immune response. Unlike wild-type mice where a greater percentage of CD4 T cells expressed CD25 and Foxp3 in response to conidia, IL-17<sup>−/−</sup> mice did not see an increase in the percentage of T<sub>reg</sub> within the pool of CD4 T cells (Figure 4-6B). However,
within the lymph node there were no statistically significant differences between wild-type and IL-17\(^{-/-}\) mice at any time point.

Similarly, there was very little difference in CD4 T cell cytokine expression between wild-type and IL-17\(^{-/-}\) mice. The percentage of CD4 T cells expressing IFN-\(\gamma\) or IL-4 showed no significant differences at any time point (Figure 4-7). Predictably, there were no detectable IL-17-producing CD4 T cells in the IL-17\(^{-/-}\) mice. Given the disparity in T\(_{reg}\) percentage, it is perhaps unsurprising that there was a difference in IL-10 production following two challenges. The discrepancy between the two strains may help explain the presence of hypersensitivity and eosinophilia in WT and not IL-17\(^{-/-}\), as we have previously shown that IL-10\(^{-/-}\) mice have a dampened inflammatory response to repeated \(Af\) conidia challenge (29).

**IL-17 hinders clearance of viable conidia from the lung, but clearance is not associated with a particular cell type.**

One of the biggest differences seen between wild-type and IL-17\(^{-/-}\) mice is the ability to clear fungi (21). Therefore we wished to determine if IL-17 was a hindrance or benefit to clearance of conidia in the lung. Whereas wild-type mice were unable to efficiently clear conidia after even eight challenges, we found that after four challenges IL-17\(^{-/-}\) mice were significantly better at clearing conidia than their wild-type counterparts (Fig. 4-8). After two challenges – and before the adaptive immune system has been activated – both mouse strains had identical clearance of \(A.\ fumigatus\) from the lung. However, by four challenges the IL-17\(^{-/-}\) mice had significantly lower numbers of viable conidia in the lung. Moreover, while there is a significant difference between the two mouse strains during hypersensitivity, the IL-17\(^{-/-}\) mice are significantly better at
clearing conidia after four challenges than they are following two challenges. This enhanced clearance is maintained throughout the course of the exposure.

Given the enhanced clearance in IL-17\textsuperscript{-/-} mice, we wanted to see if there was the same correlation between viable conidia and cell types as in wild-type mice. As before, XY scatter plots were generated from mice that had been challenged four times and regression analysis was used to determine if there is any relationship between cellular levels and viable conidia. Unlike wild-type mice, there is no significant correlation between any cell type and the number of viable conidia in the lung (Fig. 4-9). As with wild-type mice there is a strong but not statistically significant negative correlation between the number of B cells and viable conidia. Similarly, there was a positive correlation between the number of viable conidia and the number of Group III and Group IV cells. These relationships did not reach significance, however, though the trends were similar to the relationship seen in WT mice following four challenges.
Figure 4-1. IL-17<sup>−/−</sup> do not have increased susceptibility to lethal fungal infection. Mice were challenged intranasally with 2 x 10<sup>6</sup> live conidia once a week for eight weeks. Shown is the survival of all mice in the cohort over the course of eight weeks. Solid line indicates WT; dashed line indicates IL17<sup>−/−</sup>. 
Figure 4-2. Lack of IL-17 attenuates hypersensitivity response but does not dampen the chronic inflammatory response. (A) Total cells in the lungs node were calculated by counting total live cells in both tissue types and multiplying by the percentage of cells that were CD45<sup>+</sup>. Cell populations were identified as described in Figure A-1. All columns represent the average of at least four separate experiments. Black columns = WT mice; white columns = IL-17<sup>−/−</sup> mice. Starred bars indicate p < .05. (B) Lymphocyte numbers in the mediastinal lymph node.
Figure 4-3. Basophil levels are unaffected by the lack of IL-17 during acute and chronic inflammation. Basophils were identified by gating for FSC\textsuperscript{low} SSC\textsuperscript{low} Gr1-CD11c- cells, then gating out T cells and B cells (CD3+ and CD19+ cells). The remaining cells that were CD49b+ FceRI+ were classified as basophils. The mean number of basophils following zero, two, four, and eight challenges is shown. Black columns = WT mice; white columns = IL-17\textsuperscript{-/-} mice. Starred bars indicate p < .05.
**Figure 4-4.** IL-17^{−/−} mice show reduced cellular infiltrate but are still capable of mucus-hyper-secretion and multi-nucleated macrophage formation. Lungs from mice challenged zero, two, four, or eight times were fixed in formalin and embedded in paraffin blocks. Histological slices were then stained with H&E or PAS. (A) Slides were examined at 40X magnification. Arrows indicate eosinophil and neutrophil infiltrate. In PAS staining, bright purple cells indicate mucus secretion. (B) In mice challenged four times with conidia, multinucleated macrophages were observed in the lungs. Magnification is 100X.
Figure 4-5. Reduced eosinophil infiltrate can be observed in IL-17⁻/⁻ mice following four challenges with \textit{Af} conidia. Aliquots of leukocytes from WT and IL-17⁻/⁻ mice challenged zero, two, four, and eight challenges were stained with a Wright-Giemsa stain set and observed at 40X magnification.
Figure 4-6. T cell activation is unaffected in IL-17⁻/⁻ mice, but there is a decrease in the CD4 regulatory phenotype following two challenges. (A) Lung cells were stained antibodies for CD45, CD4, CD44, and CD69. CD4 T cells were isolated via gating and those that were CD44<sup>High</sup> CD69<sup>+</sup> (FLOW gate) were counted as activated. Each time point is a representative concatenation of three samples. Both the percentage and total number of activated CD4 T cells in the lung and lymph nodes was calculated for each mouse and averaged for each time point. n ≥ 6 for each time point. (B) Cells taken from both lung and mediastinal lymph node were stained for CD45, CD4, and CD25. Following permeabilization cells were then stained for intracellular Foxp3 expression. Effector:Treg ratio was determined by comparing the percentage of CD4 T cells that were double-positive for CD25 and Foxp3 to those that were double-negative. Bars represent the mean of each mouse at each time point. n ≥ 6 for each time point. Black columns = WT mice; white columns = IL-17⁻/⁻ mice. Starred bars indicate p < .05.
Figure 4-7. **IL-17<sup>-/-</sup> mice do not produce IL-10 in response to initial conidia challenges.** Cells taken from lung were stimulated for six hours with PMA and Ionomycin and then stained with fluorescently labeled antibodies specific for CD45 and CD4. Following permeabilization cells were then stained for intracellular IFN-α, IL-4, IL-10, and IL-17 expression. The mean percentage and mean total number of CD4 T cells expressing each cytokine is shown. Black columns = WT mice; white columns = IL-17<sup>-/-</sup> mice. Starred bars indicate p < .05.
Figure 4-8. IL-17−/− mice have enhanced clearance of conidia following four and eight challenges. Following digestion of the lungs an aliquot of digest was serially diluted and plated on SDA media and hyphal foci were counted. The graph shows the average viable conidia per lung detected 24 hours after zero, two, four, and eight challenges. Black columns = WT mice; white columns = IL-17−/− mice. Starred bars indicate p < .05.
Figure 4-9. Cell numbers do not correlate with conidia clearance in IL-17<sup>+/−</sup> mice during peak inflammation. Following 4 conidia challenges, the number of viable conidia per IL-17<sup>+/−</sup> mouse was compared to individual cell populations in each lung. Each point represents the number of viable conidia vs. the number of cells in an individual mouse. Slope, y-intercept, R<sup>2</sup> value, and p-value were determined using regression analysis.
Discussion

We show here that IL-17 plays a significant role in exacerbating hypersensitivity to *Aspergillus fumigatus* conidia. Whereas wild-type mice have a burst of cellular infiltration after four challenges that recedes over the next several weeks, cellular levels in IL-17−/− mice plateau after four challenges and stay relatively constant with the exception of the neutrophil population. In the lymph node, CD4 and CD8 numbers are almost identical. Differences are due almost entirely to B cell levels which is not unexpected given the role of IL-17 in driving germinal center B cell differentiation (30).

What *is* surprising is the abrogation of eosinophilia in the lung following four challenges. Several previous studies have examined the role of IL-17 in pulmonary hypersensitivity models using modified protocols of the traditional OVA-asthma model. In almost every case it was found that IL-17 knockout mice had similar (1, 26, 31) or increased (27) levels of eosinophils in the bronchoalveolar lavage fluid. The only time eosinophil abrogation has been observed is in mice unable to produce the IL-17 receptor (IL-17R). However, IL-17 and IL-25 share the IL-17RA (32), and the knockout strain used was IL-17RA−/−. IL-25 plays a central role in Th2 allergic inflammation (33-36), so it is unsurprising that knocking out the IL-25 receptor would reduce eosinophilia in the lung. Thus, the attenuation of eosinophilia in response to *A. fumigatus* conidia represents a novel observation within the scientific field.

Despite the importance of an IL-17 role in eosinophilia, there are other differences between the wild-type and IL-17−/− mice that provide tantalizing clues as to the role of Th17 in the pulmonary hypersensitivity response. First, and least surprising, lack of IL-17 results in a significantly reduced number of neutrophils. This is to be expected as several previous studies of IL-17 and asthma have found that IL-17 knockout
or depletion abrogates neutrophilia (26). Puzzlingly though, there was no difference in precursor levels at any time point despite a proven role for IL-17 as a monocyte chemotactic agent (37), yet there were significant differences in numbers of dendritic cells after four challenges and macrophages after four and eight challenges. Since precursors are required for both dendritic cells and macrophages, why then are the numbers between the two mouse strains virtually identical? These data suggest the intriguing possibility that IL-17 may play a role in cellular differentiation.

Of course, it is also possible that differences in total cell numbers and cellular composition directly affect differentiation and that IL-17 is merely an upstream mediator not a direct effector of the process. Certainly, the role of IL-17 in cellular trafficking and signal induction is not disputed. IL-17 is capable of upregulating production of a number of CXCR3 agonists including CXCL9, CXCL10, and CXCL11 (8). It can enhance epithelial release of β-defensins, I-CAM-1, IL6, IL-8, CXCL1, CCL20, G-CSF, MUC5B, and MUC5AC (38), induce GM-CSF production (39) (which in turn enhances T\_H\_17 development (40)), and can even enhance chemokine gene expression by stabilizing mRNA transcripts (41). It is therefore possible that IL-17 is affecting differentiation and cytokine production by altering the quantity of cells as well as their function. Indeed, it has been previously shown that IL-17, IL-23, and IL-25 can all alter eosinophil cytokine production and release (42), and GM-CSF can alter the function and survival of both eosinophils and neutrophils (43).

The same logic can be applied towards the clearance of conidia. We show that after repeated exposure IL-17\(^{-/-}\) mice are significantly more efficient at clearing conidia from the lungs. Again, this is most likely due to a downstream consequence of IL-17 production rather than a direct effect on local cells. Previous reports have shown that IL-
17 can dampen the killing efficacy of neutrophils by altering IDO production (21). Likewise, IL-17 can worsen inflammation and downregulate regulatory T cells (44), T_{REG} in particular having been shown to play a role in fungal clearance (45). However, differences in T_{REG} levels are only seen after two challenges when there is no difference in fungal clearance but are identical after four and eight challenges when fewer viable conidia can be detected in IL-17^{-/} mice. Thus, differences in clearance are most likely due to IDO levels or some other mechanism that is controlling the efficacy of fungal clearance.

Additionally, there is the role of IL-17 and the T_{H17} response in cytokine production and the transition from a tolerant response to a hypersensitivity reaction. While the hypersensitivity response seen in wild-type mice was absent following four challenges, mice showed an inflammatory response and greater cellular infiltrate than was found following two challenges. In IL-17^{-/} mice the response following four challenges was remarkably similar to the eight-challenge response, suggesting that while IL-17 drives the hypersensitivity response it is not responsible for the induction of the adaptive immune response. It is also possible that it plays no role in the resolution of the T_{H2} response, though without being able to generate hypersensitivity it is impossible to know for sure.

This isn’t to say that the T_{H17} response may not be playing a role in driving and/or resolving the hypersensitivity response to *A. fumigatus* conidia. IL-23, which is responsible for the maintenance of T_{H17} T cells (46) – and whose receptor is expressed on a number of different cell types – is perfectly viable in IL-17^{-/} mice and acts upstream of IL-17 (47, 48). Moreover, IL-23 has been repeatedly linked to autoimmune diseases and injurious inflammation: brain inflammation (49), autoimmunity (50), and inflammatory bowel
disease (51) have all been linked to IL-23. IL-23 levels also correlate with severity in several diseases (10, 18, 52) and the T\textsubscript{H}17 response may worsen inflammation by regulating IDO, kynurenines, and T\textsubscript{regs} levels (44). Thus it is possible that IL-23 may be responsible for initiating or resolving hypersensitivity and IL-17 serves to exacerbate the response.
References


interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. *Nature* 421:744-748.


Chapter 5
The Role of IL-17 in Eosinophil Development, Maturation, and Trafficking

Introduction

Eosinophils have been associated for years with defense against parasitic infections (1). More recently, details of their role in combating various pathogens has become more apparent. Not only can they combat vegetative fungi (2), but eosinophils express TLRs (3) and can act as APCs (4). However, it has also long been known that eosinophils play a central role in several pulmonary hypersensitivity responses (5-7) as well as tissue remodeling (8). Moreover, the cellular components that make eosinophils so effective against parasites can also result in damage to host tissue and impair function. Major Basic Protein (MBP) is a prime example. MBP is crystallized in eosinophil granules (9) and is toxic to parasites (10) and bacteria (11). Unfortunately, it is also cytotoxic to airway epithelium (12, 13) and activates remodeling factors (14). Other granulocyte factors such as eosinophil peroxidase, eosinophil cationic protein, and eosinophil-derived neurotoxin (15, 16) have anti-pathogenic effects (17) at the expense of tissue damage and mutagenesis (18-20). Thus, the presence of eosinophils in the lungs is necessary during parasitic or hyphal infection, but the hypersensitivity response provides little tangible benefits to individuals experiencing chronic exposure to conidia. The lack of eosinophilia in IL-17−/− mice in response to chronic Af exposure therefore makes IL-17 a tantalizing target for clinical therapy.
However, in order to provide a more tangible benefit, the underlying mechanism must be elucidated. Three primary possibilities exist for IL-17’s role in driving eosinophilia: IL-17 enhances bone marrow development of eosinophils, IL-17 directly or indirectly alters eosinophil maturation and activation at the inflammatory site, or IL-17 plays a central role in eosinophil trafficking to the lungs. Another possibility not examined here is that IL-17 prolongs the eosinophil lifespan in the lung.

Several previous studies have delved into the development of eosinophils from bone marrow precursors. A 1997 study by Murali et al. showed that bone marrow eosinophilia could be detected in mice with allergic bronchopulmonary aspergillosis (21), and since then the mechanism of development has been elucidated. Eosinophils arise from eosinophil-basophil precursors (22) with transcription factor composition and order affecting development (23). Actual development is controlled by the GATA-1 (24), PU.1 (25), and c/EBP (26) transcription factors, with GATA-1 being the most important (27). Surface marker expression is also distinct from other progenitor groups allowing for identification via flow cytometry (28). IL-17 has been shown to induce production of GM-CSF – a potent stimulator of granulocyte differentiation – in a dose-dependent manner (29), though conversely it has been found that IL-17 may combat GM-CSF signaling (30). Along similar lines, it has been previously shown that IL-17 depletion can enhance eosinophil production in the bone marrow during OVA-induced asthma (31). Either way, a substantial link has already been established between IL-17 and eosinophil production in the bone marrow.

Though there is no direct evidence that IL-17 affects eosinophil maturation or activation to our knowledge, several reports show a role for IL-17 in controlling the eosinophil response. IL-17, along with IL-23 and IL-25, can affect eosinophil cytokine
production and release (32). In addition, chemokines can promote the activation and function of eosinophils (33), and IL-17 has been found to enhance chemokine expression by stabilizing cellular mRNA (34). Thus it is possible that IL-17 may affect eosinophils indirectly through the release of chemokines, or we may observe a direct IL-17 role in eosinophil activation.

Probably the most logical possibility, however, is that IL-17 affects eosinophil trafficking to the lungs. Leukocyte trafficking to specific tissue is controlled by chemokines and integrins (35), and eosinophils are no exception. Eosinophils constitutively express CCR1 and CCR3 (36, 37), and knockout of CCR3 or eotaxin-1 or -2 dampens pulmonary eosinophilia (38). At least one group has concluded that the three necessary factors for eosinophilia are primed CD4 T cells, IL-5, and eotaxin-1 (39), though there is still some debate as to the role and importance of eotaxin-1 versus eotaxin-2 (40). This reliance on chemotactic agents suggests a possible role for IL-17 in eosinophil chemotaxis, as the cytokine has previously been shown to induce epithelial release of a number of molecular signals including I-CAM-1, IL-8, IL-6, CXCL-1, CCL20, and G-CSF (41). IL-17 is a direct chemotactic agent for monocytes (42) and upregulates production of CXCL 9, 10, and 11 (43). IL-17 has also been shown to play a role driving granulocytic influx during allergic responses (31), though to date only neutrophil levels have been altered by IL-17 knockout or depletion (41). It is therefore reasonable to think that IL-17 may be playing a role in controlling eosinophil trafficking to the lung.

**Aims**
1. Determine the effect, if any, of IL-17 on eosinophil development from bone marrow cells during the pulmonary hypersensitivity response.

2. Determine the effect, if any, of IL-17 on eosinophil maturation and activation during the pulmonary hypersensitivity response.

3. Determine the effect, if any, of IL-17 on eosinophil trafficking during the pulmonary hypersensitivity response.

Results

IL-17<sup>−/−</sup> mice are capable of generating eosinophils in the bone marrow in response to <i>Aspergillus fumigatus</i> conidia.

There are several possible explanations for the differences seen between wild-type and IL-17<sup>−/−</sup> mice during the hypersensitivity response; our final goal was to determine the source of these differences. In particular, we wished to explore the novel observation that IL-17<sup>−/−</sup> mice lacked the eosinophilia found in their wild-type counterparts. To do this, we first examined bone marrow development in both mouse strains during the hypersensitivity response and prior to conidia challenge. Previous reports have shown that the composition of bone marrow can be analyzed by examining surface expression of CD31 and Ly6C (44, 45). Cells in the resulting flow plot are dispersed into six distinct gates (Fig. 5-1). Cellular distribution is slightly different in wild-type and IL-17<sup>−/−</sup> mice that are untreated; however during peak hypersensitivity the cellular populations converge and are nearly indistinguishable. By pooling several experiments we were able to statistically compare the composition of each group following four conidia challenges. We found that there was no significant difference in the bone marrow between WT and knockout mice during the hypersensitivity response (Fig. 5-2). To further verify similar
production of eosinophils in both mouse strains we generated cyto\- spin stains from bone marrow cells with a Wright-Giemsa stain. Eosinophils were observable in low quantities in both mouse strains regardless of *Af* exposure, and there was no obvious increase in the percentage of eosinophils in the bone marrow cells (Figure 5-3).

Interestingly, we saw something different when looking at GATA-1 mRNA production in the bone marrow. mRNA expression of GATA-1 – the primary transcription factor for eosinophil development – was unchanged in WT mice during the hypersensitivity response, indicating that the hypersensitivity response is not driving excess production of eosinophils. However, IL-17−/− mice showed a significant drop in GATA-1 mRNA production relative to wild-type mice during the same time period (Fig. 5-4). It is therefore possible that IL-17 is playing a role in driving, or at least maintaining, eosinophil differentiation during the hypersensitivity response. In either case, the reduction of GATA-1 expression in IL-17−/− mice has a rather mild effect on eosinophil production, as eosinophils are still observable in IL-17−/− in the bone marrow and blood (Figs. 5-3 & 5-9).

Lack of IL-17 does not alter the maturation or the activation of eosinophils in the lung during hypersensitivity.

A second possibility is that the lack of IL-17 is somehow affecting the potential in the lung for immature eosinophils to fully develop or for mature eosinophils to become activated. To test this, we stained cells from digested lungs with a specific set of antibodies to examine changes in eosinophil development. Of particular interest were CCR3 – a trafficking receptor for a number of chemokines including eotaxin – and the IL-5 receptor (IL-5R). CD45+ cells were first separated from the pool of total lung cells,
and then eosinophils were further isolated from the leukocyte population by gating for FSC$^{\text{low}}$ cells with a SSC$^{\text{mid-high}}$ profile (Fig. 5-5A). The eosinophil population was then analyzed by looking at expression of IL-5R and CCR3. We found that eosinophils in the lung could be subdivided into three distinct subgroups based on their IL-5R expression. These groups were labeled as IL-5R$^{\text{high}}$, IL-5R$^{\text{mid}}$, and IL-5R$^{\text{low}}$. Expression of siglec F (sigF) in each group showed that cells with high IL-5R expression had almost no sigF expression, while those that were IL-5R$^{\text{low}}$ almost universally expressed sigF (Fig. 5-7).

We then compared the cellular distribution of cells within these three gates in wild-type and IL-17$^{-/-}$ mice during the hypersensitivity response. As a positive control we performed an identical stain set on wild-type C57BL/6 mice that had previously been infected with Cryptococcus neoformans, which results in a strong T$_{\text{H}2}$ response and extreme eosinophilia. There were no obvious differences between WT and IL-17$^{-/-}$ mice that had been untreated, and there were no obvious differences between strains following four challenges (Fig. 5-5 B). However, differences could be seen between mice that were untreated, had been challenged four times, or had been infected with C. neoformans. In agreement with previous data suggesting that low IL-5R expression is associated with activation, mice that were untreated had the highest percentage of IL-5R$^{\text{high}}$ cells, while those infected with C. neoformans had nearly ninety percent of their eosinophils in the IL-5R$^{\text{low}}$ gate (Fig. 5-6 B). Using exclusively forward- and side-scatter analysis, there was a significant increase in the percentage of leukocytes that were eosinophils between untreated mice and those challenged four times (Fig. 5-6 A). Additionally, there was a significant decrease in percentage in IL-17$^{-/-}$ mice following four challenges compared to WT mice, an observation consistent with other data. The distribution of eosinophil IL-5R expression between time points was significantly different for both strains of mice, but
there was no difference between the strains (Fig. 5-6 B). Moreover, within each of the three gates there was no difference in surface expression of siglec F between wild-type and IL-17\(^{-/-}\) mice following four challenges (Fig. 5-7). Thus, IL-17 does not play a direct role in driving eosinophil activation or maturation.

**IL-17 drives cellular recruitment to the lung during acute hypersensitivity to Aspergillus fumigatus conidia.**

The most logical remaining explanation for the reduced numbers of eosinophils in the lungs is trafficking. Previous reports have shown that IL-17 is responsible for inducing the release of a number of chemokines from epithelial cells, and it possible that a lack of IL-17 prevents cells from reaching the lung during infection (42, 43). Cell surface expression of trafficking markers on non-granulocytic myeloid cells in the lung supports this. In the lungs, CD11b expression shows that the percentage of new cells is much greater in WT mice than in IL-17\(^{-/-}\) mice (Fig. 5-8). This is particularly true in macrophages and Group IV cells. Moreover, siglec F – which is expressed on resident macrophages – is reduced in wild-type mice, further supporting this observation. There are also small differences in dendritic cell expression, but these are not nearly as pronounced. Similarly to eosinophils, differences in NGMC between the two mouse strains seems to be limited to cellular levels and not activation. CD80 and CD86 expression is identical to that seen in untreated mice and is the same in both WT and IL-17\(^{-/-}\) mice following four challenges (Fig. 5-8).

To see if inhibited trafficking to the lung was responsible for the dearth of eosinophils observed during the inflammatory response in IL-17\(^{-/-}\), we took whole blood from mice challenged four times and analyzed the number of leukocytes and the cellular
composition. Following isolation from the blood, cells were gated for CD45 expression and then isolated via CD11b surface expression. CD11b$^+$ cells were then broken down into two groups: eosinophils – SSC$^{\text{high}}$ – and small myeloid cells – FSC$^{\text{low}}$ SSC$^{\text{low}}$ – consisting of neutrophils and monocytes (Fig. 5-9 A). In uninfected mice, there was no significant difference seen between WT and IL-17$^{-/-}$ with regards to total leukocytes, eosinophils, or small monocytes. However, there was a striking and significant difference between cell levels in WT and IL-17$^{-/-}$ mice that had been challenged four times (Fig. 5-9 B). Moreover, while there was a significant difference between untreated and four-challenge IL-17$^{-/-}$ cell levels for all cell types, there was a much more modest – and not statistically significant – difference between untreated and four-challenge wild-type mice. The data therefore show a buildup of leukocytes in the blood of IL-17$^{-/-}$ mice that is not present in WT mice during hypersensitivity. This suggests then that the lack of IL-17 is altering pulmonary levels of leukocytes by preventing extravasation from the blood to the tissue at the site of infection.
Figure 5-1. WT and IL-17−/− mice show identical bone marrow differentiation in response to repeated pulmonary conidia challenge. Bone marrow isolated from WT and IL-17−/− mice challenged zero and four was stained with Ly6C and CD31. Cells segregated into six distinct populations designated I-VI.
Figure 5-2. Bone marrow differentiation is unchanged in IL-17κ/κ mice during peak inflammation. The total percentage of cells within each gate was averaged for each mouse strain following zero or four challenges. For untreated mice, n = 3; for mice challenged four times n ≥ 11.
Figure 5-3. WT and IL-17−/− mice bone marrow shows no obvious phenotypic differences following chronic exposure to conidia. Aliquots of leukocytes from WT and IL-17−/− mice challenged zero, two, four, and eight challenges were stained with a Wright-Giemsa stain set and observed at 40X magnification.
Figure 5-4. Bone marrow from IL-17/- mice shows a significant reduction in production of GATA-1 mRNA. RNA from WT and IL-17/- bone marrow was isolated after zero and four challenges. Following conversion to cDNA, GATA-1 levels were measured for each individual mouse. For untreated mice, n = 3; for mice challenged four times n ≥ 6. Black columns = WT mice; white columns = IL-17/- mice. Starred bars indicate p < .05.
Figure 5-5. Lung eosinophils show increased maturity in response to antigen challenge. (A) Eosinophils were separated from the cellular background by selecting CD45+ cells that were FSC_{low} SSC_{mid-high}. The enriched population was then analyzed for IL-5R and CCR3 surface expression. The eosinophil population was then divided into three distinct gates: High, Mid, and Low. (B) The FSC/SSC profile and IL-5R/CCR3 expression of lung eosinophils in WT and IL-17^{-/-} mice was compared following zero and four challenges. The expression profile of lung eosinophils from C57BL/6 mice infected with *C. neoformans* is also shown and serves as a positive control.
Figure 5-6. Lung eosinophils maturity is unaffected by a lack of IL-17. (A) Using FSC/SSC profiles, the percentage of lung CD45+ cells that were eosinophils was plotted. (B) Within the eosinophil population, the percentage of cells that fell within the High, Mid, and Low gates was plotted for WT and IL-17−/− mice following zero and four challenges, as were eosinophils from *C. neoformans-*infected mice. For untreated mice, n = 3; for mice challenged four times n ≥ 11. Black columns = WT mice; white columns = IL-17−/− mice. Starred bars indicate p < .05.
Figure 5-7. Expression of siglec F on eosinophils is governed by cell maturity and is unaffected by fungal exposure or the presence of IL-17. Cells within the High, Mid, and Low gates were analyzed using histograms for their expression of siglec F. Solid black lines = WT mice; dashed gray lines = IL-17−/− mice, gray peaks = IgG controls.
Figure 5-8. Lack of IL-17 does not alter myeloid activation but reduces the influx of new cells into the lung. Non-granulocytic myeloid cells were examined for their expression of cell surface markers. Solid black lines = WT mice 4x challenge; dashed gray lines = IL-17<sup>−/−</sup> mice 4X challenge, gray peaks = WT untreated mice.
Figure 5-9. IL-17−/− mice show increased numbers of eosinophils and other myeloid cells in the blood during peak inflammation. Blood was collected from WT and IL-17−/− mice following zero and four conidia challenges. (A) Following cell counting, cells were stained for flow cytometry. CD45+ CD11b+ CD11c<sub>low</sub> cells were gated and their FFSC/SSC profile analyzed. (B) The total number of CD45+ cells was measured in the blood of WT and IL-17−/− mice. Additionally, the number of eosinophils and small myeloid cells was plotted. For untreated mice, n = 3; for mice challenged four times n ≥ 11. Black columns = WT mice; white columns = IL-17−/− mice. Starred bars indicate p < .05.
Figure 5-10. IL-17⁻/⁻ mice are predicted to have less IL-5 in the lungs during peak inflammation. Red triangles indicate IL-5, black forks indicate IL-5R. Immature eosinophils are represented expressing IL-5R, while mature eosinophils have shed the receptor into a soluble form.
Discussion

We show here that IL-17 plays several roles in regulating eosinophil levels in the lung during the hypersensitivity response. Firstly, IL-17 has a modest role in driving, or at least maintaining, eosinophil differentiation in the bone marrow. Secondly, IL-17 has a direct role in cellular recruitment, and during conidia-induced pulmonary hypersensitivity it plays a role in eosinophil trafficking from the blood to the lungs. Thirdly, IL-17 appears to not play a role in the maturation of eosinophils, though there is a distinct possibility that it may indirectly play a role in shaping the eosinophil population in the lungs.

The data regarding bone marrow differentiation are somewhat conflicting. Based on the flow and cytospin data, one would conclude that eosinophil production from the bone marrow is unchanged in IL-17−/− mice. However, GATA-1 mRNA is reduced in the bone marrow. A reduction in eosinophil production makes sense of course, as eosinophils express the GM-CSF receptor (46) and GM-CSF plays a big role in eosinophil development along with IL-3 and IL-5 (46-49). How does one then reconcile the data? The most likely answer is that IL-17 does play a small role in BM eosinophil development, but the effects are not obvious due to the relatively modest eosinophil response. First, IL-17−/− mice are still plainly capable of generating eosinophils as evidenced by the cytospin data, the low levels in the lung during hypersensitivity, and the buildup of CD11b+ cells in the blood. Moreover, the change in GATA-1 levels seen in wild-type mice is negligible during hypersensitivity, and visual inspection does not show differences between either mouse strains at either time point. Thus, the hypersensitivity response does not result in the generation of many new eosinophils even in wild-type
mice, and it is likely that even reduced eosinophil production in IL-17⁻/⁻ mice is enough to maintain levels in the blood.

This concept is bolstered by the method in which eosinophils are kept in reserve in mice. Unlike other myeloid cell types, eosinophils first traffic to the peritoneum where they pool to form a cellular reservoir (50). Even during parasitic infection it was found that the majority of eosinophils at the site of infection had come not from the bone marrow, but from the peritoneum. This then could explain why there were still eosinophils in the blood, even if production was reduced in the bone marrow: the eosinophils had been generated prior to infection and had come from the cellular reservoir. This might help explain why previous IL-17 depletion studies using OVA-sensitization have not noticed differences in eosinophil levels (41). These studies focus almost entirely on acute eosinophilia shortly after the allergic response is triggered. Since the eosinophils are coming from the peritoneum rather than the bone marrow, it’s likely that cellular levels are being measured before the cellular reserve is depleted.

This of course does not entirely explain the unchanged eosinophil levels seen in IL-17⁻/⁻ mice using OVA protocols, as we also show that IL-17 plays a role in cellular trafficking to the lung. There are several ways in which IL-17 might be affecting eosinophil trafficking. Aside from chemokine production, IL-17 might conceivably be altering expression of integrins that are used for rolling, tethering, adhesion, and transendothelial migration (51). However, given the similar integrin use of eosinophils and basophils, it is more likely that eosinophil-specific chemokines are altering recruitment as basophil levels are unchanged in IL-17⁻/⁻ mice.

It is likely then, that IL-17 affects eosinophil trafficking by altering chemokine expression, probably eotaxin. Whereas dendritic cells have been shown to be responsible
for driving $T_h$1 chemokine production in response to *Aspergillus fumigatus* (52), the main recruiter of airway eosinophils is suspected to be eotaxin-2 produced by macrophages (53). Since we have shown that a lack of IL-17 results in diminished macrophage recruitment, it is possible that IL-17 drives the accumulation of macrophages which in turn drives the accumulation of eosinophils. Certainly it has been shown that monocytes – the precursors to macrophages – express the IL-17 receptor and use IL-17 as a chemotactic agent (42). However, it is clear, not only from our observations but from the literature, that some mechanistic redundancy must exist or eosinophils would not be able to reach the lungs at all. Eosinophils have been shown to upregulate expression of other chemokine receptors in response to IL-5, and IL-5 itself can as a chemoattractant, though it is less effective than the eotaxins (54). Thus, even if IL-17 does drive one aspect of eosinophil recruitment, there are likely other paths that allow some trafficking of eosinophils to the lungs. This idea is supported by the previous allergic studies that found no drop in eosinophil levels in response to OVA hypersensitivity in IL-17$^{-/-}$ and IL-17 depleted mice. It is likely that these models induced eosinophil migration through a number of different pathways so that IL-17 knockout or depletion had little effect. In response to low doses of conidia, however, IL-17 probably plays a much more central role in recruitment.

A final, more remote possibility relates to the methods used by previous researchers. Previous studies have measured eosinophils levels by visualization, relying on cytospin counts to determine eosinophil composition. Upon activation, eosinophils degranulate, releasing stored anti-microbial compounds and cytokines at the site of inflammation. It is possible that previous studies have simply been unable to differentiate
between eosinophils and neutrophils using a Wright-Giemsa stain because, without
granules, the two cell types look nearly identical.

It is also possible, though, that IL-17 is affecting IL-5 levels in the lung, and this
is affecting not only trafficking, but development. IL-5 plays a significant role in
eosinophil development (47-49), and it is essential for expansion of the population in the
bone marrow (55). One might ask then, if there is altered IL-5 production, why is the
maturation of eosinophils during hypersensitivity the same in both wild-type and IL-17−/−
mice? In order to answer that question, one must remember that the eosinophil population
in IL-17−/− mice is one third that of WT during peak inflammation. Therefore there are
three times as many eosinophils binding IL-5 in WT mice, and there are three times as
many mature eosinophils releasing secreted IL-5 receptor into the milieu (56). This
implies that more IL-5 is present to maintain the larger population of eosinophils in WT
mice (Fig. 05-10). When we measured total cytokine production in the lung using micro
array analysis, we indeed found higher levels of IL-5 in WT mice than IL-17−/− mice
during the hypersensitivity response, though the difference did not reach statistical
significance (p > .05) (Fig. A2-5). Taken together, it is highly possible that IL-17 affects
IL-5 expression, either directly or through an intermediary. This would explain not only
the difference in trafficking, but also developmental differences and differences in
maturation. Given the difference in numbers for all cell types, it is likely that IL-17 acts
as a global regulator of inflammation during the hypersensitivity response and
downstream components of the immune system ultimately govern eosinophil recruitment
and development.
References


Chapter 6
Summary, Interpretation, Critical Review, and Future Directions

Summary and Interpretation

The studies in this dissertation can be broken down into three broad, yet distinct, categories: the characterization of the immune response to repeated pulmonary exposure to *Aspergillus fumigatus* conidia, the role of IL-17 in the hypersensitivity response to chronic conidia challenge, and the role of IL-17 in driving eosinophilia during hypersensitivity. In all three cases, the data presented here provides both novel insights into the mechanisms of the hypersensitivity response towards *Af*.

First and foremost, our research has elucidated a number of possible adaptive mechanisms during the immune response to *Aspergillus fumigatus*. Unlike previous studies which have shown the immune response to be purely adaptive (1-4) or T\(_H\)1 in nature (5-7), we find that chronic exposure to conidia results in a dynamic response characterized by early tolerance, subsequent T\(_H\)2 hypersensitivity, and, ultimately, moderate T\(_H\)17 inflammation. The hypersensitivity response is characterized by an influx of nearly all cells types; macrophages, dendritic cells, neutrophils, basophils, CD4 T cells, B cells, and the most dominant new population, eosinophils, all are significantly increased in the lung between two and four challenges. This hypersensitivity is accompanied by mucus hyper-secretion in the airways as well as formation of multinucleated macrophages. Moreover, repeated challenges did not improve the ability of the immune system to clear viable conidia from the lung, and the levels of several cells
types – myeloid precursors in particular – were significantly correlated to fungal levels. Perhaps most importantly, we observed IL-17 production that was increased following two challenges and continued to increase over the course of exposure. In particular, the expression of IL-17 and the poor clearance of conidia represent novel observations that lead to new lines of inquiry.

This led to our next series of experiments where we showed that IL-17 played a role in driving the hypersensitivity response. To our surprise, cellular levels were almost identical at all other time points in both mouse strains, but following four challenges IL-17\(^{-/-}\) mice were unable to generate the same level of inflammation as wild-type mice. In particular, IL-17\(^{-/-}\) mice showed a significant reduction in the number of eosinophils in the lungs following four challenges. To our knowledge such an observation has never been reported, as previous studies using OVA models of pulmonary inflammation similar eosinophil levels in the lungs in IL-17\(^{-/-}\) and IL-17-depleted mice.

However, aside from a reduction in IL-10 and Foxp3 production following two challenges, IL-17\(^{-/-}\) mice mounted a nearly identical, albeit dampened, inflammatory response to repeated conidia challenge. IL-4 was still produced following four challenges, epithelial cells still secreted mucus, and even basophil levels were unaffected. The only other difference we observed was a more effective clearance of conidia from the lung in the IL-17\(^{-/-}\) mice.

The observation that eosinophilia was dampened in IL-17\(^{-/-}\) mice led us to examine the mechanism behind the eosinophil accumulation in the lungs of WT mice during hypersensitivity. To do so we examined bone marrow differentiation, eosinophil maturation in the lungs, and cellular trafficking. The data regarding bone marrow differentiation was conflicting, as flow cytometric analysis and cell staining showed no
obvious differences in eosinophil development. However, expression of GATA-1 mRNA – the primary transcription factor for the eosinophil lineage (8, 9) – was reduced in IL-17−/− mice during peak inflammation. This is in opposition to our initial data, as well as a previous report showing that IL-17 depletion enhances GATA-1 expression (10). The most likely explanation is that IL-17 does play a role in bone marrow differentiation of eosinophils but one that is relatively minor. Though Hellings et al. found an increase in BM eosinophil differentiation when IL-17 depleted, the difference – while statistically significant – was relatively minor. In our model of inflammation the eosinophil infiltrate is relatively mild compared to other models that exhibit an intense T_h2 response. Thus, it is likely that differences in GATA-1 expression are not due to lower total transcript expression but increased expression of other transcripts that dampen the GATA-1 signal. Analysis of eosinophil maturation indicated that IL-17 played no role in eosinophil maturation, but our results predicted a decrease in IL-5 production. This hypothesis was supported, though not proven, by preliminary data from cytokine arrays. Analysis using ELISA or western blot will be needed to confirm these initial findings.

Finally, we showed that IL-17 drove the accumulation of new myeloid cells in the lung, and IL-17−/− mice had a buildup of eosinophils and other small myeloid cells in the blood during the inflammatory response. This indicated that the dearth of eosinophils in the lungs in IL-17−/− mice during the hypersensitivity response was due mainly to poor trafficking, though the data suggests IL-17 may play a smaller role in bone marrow differentiation as well as IL-5 production. It is currently known that IL-17 can affect the production of a number of chemotactic signals; IL-17 can drive IL-5 and GM-CSF production, and IL-17 itself is used as trafficking signal by monocytes. To our knowledge, however, IL-17 has not been shown to play a role in driving eotaxin
production or integrin expression. Therefore the data presented here generate new avenues of research with regards to IL-17 and cellular trafficking.

The study provided in these pages introduces several novel observations and adds to our understanding of mechanisms that have been previously shown by other researchers. Using the hypersensitivity mechanism initially developed by Mairi Noverr and Andrew Shreiner, we expand upon their initial findings about the adaptive response during hypersensitivity, particularly the role of IL-17 in driving inflammation and eosinophilia. What’s more, our data are consistent with the findings of Zelante et al., namely that IL-17 negatively affects the immune system’s ability to clear conidia from the lung (11). These studies also add several novel scientific methods to the field of immunology, particularly to the role of flow cytometry and cellular identification in the lungs. Not only did we identify several myeloid precursors, but we were able to independently confirm IL-5R shedding as previously reported by Liu et al. (12). Unlike previous in vitro methods, our use of flow cytometry allows in vivo tracking of cellular movement as well as characterization of eosinophil maturity in the bone marrow, blood, and peripheral tissue. Together, with CD11b and siglec F expression, this approach provides an exciting new method of examining the maturity of eosinophils in response to stimuli.

**Critical Review**

The data presented here provides insights into the immune system during an allergic reaction in the lungs in response to chronic allergen exposure. There are three primary human pulmonary diseases associated with *Aspergillus fumigatus* exposure in immunocompetent individuals: hypersensitivity pneumonitis (HP), allergic
bronchopulmonary aspergillosis (ABPA), and allergic asthma. The model used in these studies shares certain features with these diseases, particularly asthma, though with any mouse model there will be limitations due to differences between mice and humans in terms of genetics, immune reactions, and basic physiology.

The mouse model of disease here has very little in common with hypersensitivity pneumonitis (also referred to as ‘extrinsic allergic alveolitis’). HP is an inappropriate inflammatory response against chronic exposure to small particles, particularly organic dust. However, microorganisms such as *Af* have also been shown to be a source of disease (13-15). In terms of both physiological reaction as well as immune reaction, HP bears little resemblance to our model of disease. Inflammation with HP results in a thickening of the alveolar wall and ultimately interstitial fibrosis, neither of which are observed in our model of allergy. Moreover, other features typically associated with HP are absent as well. While CD4 T cells play a role in our model as well as HP, in HP the CD4 response is primarily T\textsubscript{H}1 and there is a low CD4/CD8 ratio (16), whereas our model shows negligible CD8 T cell involvement.

Allergic bronchopulmonary aspergillosis is a hypersensitivity disease resulting from colonization of the airway with *Aspergillus fumigatus* (17). This occurs primarily in individuals with asthma or cystic fibrosis, most likely due to the elevated levels of mucus secretion in the lung. Our model shares some traits with ABPA, particularly an influx of innate cells into the airway as well as increased serum IgE levels. However, there are some key differences. First, we fail to see fibrosis of the lung, though we have previously shown arterial remodeling, a characteristic of ABPA (18). Second, repeated conidia challenge does not result in a colonization of the lung in our mouse model. Silver staining lung sections twenty-four hours after challenge shows that the few conidia left in the lung
are beginning to germinate but have not colonize the lung. However, it is possible that repeated exposure to germinating conidia could mimic the allergens produced by colonizing fungi. Unfortunately, ABPA is a condition which requires a previous disease—in this case asthma—in order to manifest itself. Thus the lack of a hypersensitivity response prior to four challenges suggests the allergic response in C57BL/6 mice is not ABPA.

Thus, allergic asthma bears the strongest relationship with our mouse model. Though Af has not been shown to be a cause of asthma, per se, 20-25% of individuals with asthma are skin-test positive against fungal allergens (19, 20), and previous reports have linked asthma severity to sensitivity to fungal allergens (21, 22). Asthma itself, a reversible narrowing of the airways which obstructs airflow, has a number of immunologic features consistent with what we have shown. There is peribronchial and peribronchiolar cellular infiltrate, airway eosinophilia, metaplasia and mucus hypersecretion, and an increase in T\textsubscript{h}2 cells and cytokines in both the disease and the mouse model (23). There are some key differences, however, between our mouse model and asthma. Most importantly, mice challenged repeatedly with Af do not exhibit many of the physiologic changes that characterize the asthmatic response. Histological examination does not reveal a narrowing of the airways nor any remodeling. Moreover, previous studies in the laboratory using this model have shown that mice challenged multiple times with Af conidia do not exhibit airway resistance using methacoline challenge, though C57BL/6 mice have been shown to be poor responders during this assay (24-26). As such, we cannot say that we are modeling asthma, however mice challenged repeatedly with conidia develop an allergic airway disease with most of the immunologic characeristics of asthma. This is important because while asthma is defined
by physiologic responses, it is ultimately driven by the host immune system (not always – sometimes asthma can be triggered by physical stimuli) and an understanding of the host immune response is central to any treatment. Both asthma and HP can arise from nearly identical environmental factors (27, 28), highlighting the importance of host immunity in driving disease as well as skewing the response towards a TH1 or TH2 reaction.

Several previous models of murine allergic airway disease have been generated by different groups in an attempt to elucidate immune pathways during pulmonary allergic reactions. The three primary methods of generating a response are repeated conidia exposure (29, 30), IP OVA sensitization and subsequent challenge (31, 32), and Af antigen bound to inert particles (33). The main benefit of our model is that it simulates the method by which an individual would be chronically exposed to Af, namely though repeated inhalation of fungal spores (34), albeit with a more strictly regimented timeline. In addition, the dose used is physiologically relevant, consistent with one found in a damp, musty environment or even a construction site (35). Thus, as compared to previously used models of pulmonary sensitization, our model more closely resembles environmental conditions encountered outside of a laboratory environment.

Our results provide several novel observations that may further aid in the study of allergic airway disease. First and foremost, we show that IL-17−/− mice have decreased eosinophilia during a TH2-type response, something not seen before with knockout mice or IL-17-depleting antibodies (36) This new observation is most likely due to the method of sensitization: unlike previous studies viable conidia was used rather than fungal antigen, thereby creating a more complex and nuanced immune response. It is also possible, however, that the use of flow cytometry rather than simple cytospin allowed a
more nuanced analysis of the cellular population during inflammation. This lack of eosinophilia was accompanied by a buildup of eosinophils and total leukocytes in the blood, implying a possible role for IL-17 in extravasation. Moreover, we observed an initial regulatory response to low levels of inhaled conidia that is consistent with previous reports (37, 38) as well as observations previously made with our mouse model (39), suggesting that the regulatory response somehow plays a role in initiating or even driving the inflammatory response. Similarly, IL-17 plays a role in the hypersensitivity response by exacerbating the cellular infiltrate following four challenges, consistent with previous reports (10, 40-42). Finally, we observed a decrease in the T\textsubscript{H}2 response following chronic exposure to conidia that correlates with an increase in the T\textsubscript{H}17 response. This suggests a possible role for T\textsubscript{H}17 in regulation of T\textsubscript{H}2, something that has not been previously demonstrated in the literature. Taken together, our results show or suggest new roles for several cytokines including IL-17 and IL-10, as well as role for T\textsubscript{H}17 and T\textsubscript{reg} in initiating – and in the case of T\textsubscript{H}17 resolving – the hypersensitivity response during allergic airway disease.

**Future Directions**

The data presented here opens up a wide range of possible future directions. Along with a continued examination of trafficking signals during inflammation, many intriguing lines of inquiry arise from observations made during the hypersensitivity response to *Aspergillus fumigatus*. Possible future directions range from hypersensitivity induction to eosinophil maturation.

The first and most obvious project involves elucidating the mechanism by which hypersensitivity is induced in the first place. Andrew Shreiner previously demonstrated
that a lack of IL-10 abrogated eosinophilia (39), and in Chapter 3 we demonstrated that the early response to conidia involved increased IL-10 production as well as an increase in the percentage and number of regulatory T cells. This suggests that the regulatory response has an early role in activating the adaptive immune response somehow. This is counterintuitive, however, as the hypersensitivity response is characterized by T_{H2} cytokines and regulatory T cells have been shown to attenuate T_{H2} allergic hypersensitivity (43). In fact, T_{reg} and the T_{H2} responses are mutually antagonistic, as IL-4 inhibits induced-T_{reg} formation (44, 45). How then are IL-10 and regulatory T cells responsible for driving a T_{H2} hypersensitivity response? Given the suppression of IFN-γ seen over the course of exposure, one possible explanation is that suppression of T_{H1} creates a sort of vacuum that the T_{H2} response moves in to fill. Many of these ideas could be tested using antibody depletion models or by the addition of specific cytokines during inflammation. The addition of IL-17 during the early response might accelerate or exacerbate the inflammation following four challenges. Likewise, addition of IL-17 during the hypersensitivity response may accelerate the rate at which the inflammatory response is resolved. Similarly, T_{reg} depletion prior to sensitization may attenuate inflammation given the early regulatory response in reaction to a low number of conidia challenges.

What’s more, we know that IL-4 is produced during the hypersensitivity response, but we don’t know how strong that expression is relative to other models such as C. neoformans infection. It has been previously shown that T_{reg} dampen the T_{H2} inflammatory response but do so by controlling IL-4 and not IL-5, which is controlled by IFN-γ (46). This data concept is supported in our model by microarray data (Fig. A2-5) where IL-5 is shown to be upregulated in WT mice during hypersensitivity. Thus, there
are several experiments that could be introduced to try to alter the hypersensitivity response. The first, and simplest, is to use IL-5−/− mice and determine whether a lack of IL-5 significantly affects inflammation and subsequently use IL-5 depletion. Certainly it will reduce or abrogate eosinophilia (47, 48), but it is also possible that IL-5 plays a role in hypersensitivity given its role in chemotaxis (49, 50) and IL-13 production (51).

A similar possibility mentioned in Chapter 4 is that IL-23 plays a role in driving hypersensitivity since it functions upstream of IL-17 (52, 53). Given its links to other forms of inflammation, it would be interesting to see if it also played a role in allergy. Once again, IL-23 depletion or IL-23−/− mice would be useful, the latter already available as p19−/− mice (11). Also intriguing is the resolution of the hypersensitivity response. Between four and eight challenges the hypersensitivity response is dampened and eosinophilia is reduced. While several reports have indicated that IL-17 exacerbates TH2 inflammation (40, 41), the addition of IL-17 at specific times can attenuate a TH2 allergic response (10, 54). Moreover, our studies show that during chronic exposure to conidia the number of IL-17-producing CD4 T cells continues to climb, even as the hypersensitivity response is resolved. Could then IL-17 play a role in regulating TH2? If so, this could explain why asthma is frequently ‘outgrown’: the TH17 response eventually suppresses and replaces TH2. This could be tested by depleting IL-17 once the hypersensitivity response has been induced, or by adding IL-17 prior to inflammation to try to abrogate the response.

Interestingly, we found that viable conidia seemed to be more important in priming of the hypersensitivity response than in actually triggering it. Unintentionally, we administered conidia with lower viability to two mice to examine four-challenge hypersensitivity but did this after using normal, fully viable conidia for the first two
challenges. Under these circumstances mice were still able to generate a robust hypersensitivity response. However, when one viable challenge was followed by three semi-viable challenges the response was significantly dampened. This suggests that multiple challenges of viable conidia are needed to prime the immune system for a hypersensitivity response, while a small dose is capable of initiating it. Possible future studies could examine the role of viable versus semi-viable conidia in the allergic response by alternating exposures and timing.

Also interesting is the timing of hypersensitivity. We have found that cohorts of mice display variable hypersensitivity over the course of conidia exposure which is most likely due to the viability of the conidia (55). In a recent exposure regimen we observed that mice challenged eight times had a similar pattern of expression as those exposed four times in previous assays, something we had never seen before. This anomaly occurred when we used a conidia stock that were subsequently shown to have lower viability than primary stock. Therefore it is entirely possible that the viability of the conidia determines not only the strength but also the kinetics of the hypersensitivity response. If this were the case then repeated low doses of an allergen would ultimately result in an allergic response similar to higher doses, but over a prolonged period of time and with a longer buildup. The kinetics of this process would be an interesting focus of research, especially as it pertains to asthma in the general populace. Since non-viable – or simply old – conidia are presumably responsible for the delayed reaction, one could measure kinetics of the response by mixing fresh and aged/non-viable conidia together in distinct ratios and observing the rate at which hypersensitivity is generated.

Looking at eosinophils, there are several signaling pathways to examine in regards to trafficking. Though our data suggests a decrease in IL-5 due to lack of IL-17
production, it is possible that other signals are affected. Eosinophil trafficking involves IL-4, IL-5, and IL-13 (56), and both Eotaxin-1 and -2 play central roles in eosinophil recruitment (57, 58). Moreover, now that microarrays have been used to survey of the molecular signal landscape – including leukotriene expression – (Fig. A2-5), a more thorough analysis using ELISA or western blotting might shed light onto the role of IL-17 in allergic hypersensitivity. Finally, an examination of eosinophil survival could add a final piece to the puzzle in elucidating the role of IL-17 in this model.
References


Appendix 1

CD4 T Cells Are Not the Sole Contributors of IL-17

Introduction

Based on the central role of CD4 T cells in generating the hypersensitivity response, we treated – to some extent – CD4 T cells as the primary producers of IL-17. However, there are several other sources of IL-17. Lymphoid tissue inducer-like cells have been shown to be innate sources of IL-17 (1) as have γδ T cells (2). Moreover, several myeloid cell lines express IL-23R and are capable of generating IL-17 (3), and IL-17-producing macrophages have been shown to mediate allergic lung disease (4).

We therefore wished to examine whether CD4 T cells were truly the primary source of IL-17 or whether other cell types may be playing a role in production. To do this, we isolated CD4 T cells from the spleen of WT and IL-17−/− mice challenged four times with Af conidia. Cells were enriched using MACS and adoptively transferred into naïve wild-type mice. Twenty-four hours after injection mice containing transferred T cells were challenged with conidia following the standard protocol, then challenged seven days later and harvested. Cell numbers were compared between mice receiving WT 4X CD4 T cells and IL-17−/− 4X CD4 T cells.

Aims

1. To determine the source of IL-17 during pulmonary hypersensitivity to Aspergillus fumigatus conidia.
Figure A1-1. CD4 T cells for adoptive transfer are > 80% pure. Leukocytes were isolated from the spleens of WT and IL-17−/− mice challenged four times with Af. CD4 T cells were enriched using the MACS system and then stained for CD3 and CD4 to verify purity.
Figure A1-2. CD4 T cells from both WT and IL-17−/− elicited a similar early hypersensitivity response to conidia challenge. Following adoptive transfer of CD4 cells harvested from WT and IL-17−/− mice challenged four times with conidia, naïve WT C57BL/6 mice were challenged twice with *A. fumigatus* conidia. Twenty-four hours after final challenge lungs were enzymatically dispersed, and cells were counted and analyzed by FLOW cytometry. Mice challenged twice with no adoptive transfer were used as controls. For two-challenge mice n = 3, for adoptively transferred mice n = 8. Black columns = WT mouse; white columns = IL-17−/− 2-challenge mice and WT mice receiving IL-17−/− CD4 T cells and challenged twice.
Discussion

We wished to see if CD4 T cell production of IL-17 was solely responsible for the hypersensitivity response seen following four challenges. The data provided here suggest that while CD4 T cells play a role in producing IL-17, other sources may be involved as well.

Adoptively transferring CD4 T cells to naïve mice accelerated the rate at which certain cell types began to appear in the lung. In particular, dendritic cells, basophils, and eosinophils all showed a significant increase when mice were primed with transferred CD4 T cells. However, there was no significant different seen between mice that had received T cells from WT mice or IL-17⁻/⁻ mice. This suggests that other IL-17 producing cells are responsible for the additional cells levels, while the CD4 T cells are merely accelerating the process.

One potential problem with this assay was the lag time between mouse harvest and subsequent adoptive transfer. Spleens were collected during the flow of a mouse harvest, and CD4 T cells were not purified until several hours after that. Following purification, there was another wait before the cells could be adoptively transferred. Given the long lag time and relatively short life of a CD4 T cell away from a source of stimulation, it is possible that greater differences would be seen if the cells had been enriched and transferred in a more hurried fashion.
References


Appendix 2
Protocols and Odds and Ends

Introduction

The following figures contain exposure timelines, gating strategies, and other random data that did not fit directly into the narrative of this dissertation.

In the case of the microarray data, n values were too low and error bars too high for me to place the data alongside observations that were much more concrete.

Nonetheless, I find the data supports assertions made in Chapters 3, 4, and 5 and could serve as a valuable jumping-off point for future studies.
Figure A2-1. Timeline for pulmonary *Af* conidia challenge. Naïve WT and IL-17−/− mice were challenged weekly with 2 x 10⁶ live *Af* conidia. Mice were harvest twenty-four hours after two, four, and eight challenges.
Figure A2-2. Gating strategy for enzymatically dispersed lung leukocytes. Following enzymatic digestion, purification, and counting, cells were stained with fluorescently labeled antibodies and analyzed using FLOW cytometry. All leukocyte populations were first separated from epithelial cells by CD45 gating. Eosinophils and neutrophils were identified by CD11c Gr1 gating: eosinophils are CD11c\textsuperscript{mid} Gr1\textsuperscript{mid} siglec F+ and neutrophils are CD11c\textsuperscript{low} Gr1\textsuperscript{high}. Lymphocytes were identified by gating on cells with a low forward- and side-scatter profile then observing CD4, CD8, or CD19 expression. B cells (CD19) is not pictured. Non-granulocytic myeloid cells were examined by removing low forward-scatter cells and neutrophils. The remaining cells fell into four distinct groups labeled I-IV.
Figure A2-3. CD4 T cells stimulated with PMA and Ionomycin are activated. Cells were isolated from a naïve, unchallenged mouse. Following stimulation, cells were stained for CD4, CD44, and CD69. The change in expression indicates that (a) stimulation was successful and (b) that the activation gating strategy is viable.
Figure A2-4. Eosinophils start Gr1+ CD11c\textsuperscript{low} but change their surface expression pattern as they mature. Lung eosinophils were stained with IL-5R, CCR3, CD11c, and GR1. As cells matured from IL-5R\textsuperscript{high} expression cells to IL-5R\textsuperscript{low} they migrated within the CD11c Gr1 plot. There was, however, no particular correlation between size and activation.
Figure A2-5. Hypersensitivity differentially alters the cytokine make-up of WT and IL-17\textsuperscript{−/−} mice. WT and IL-17\textsuperscript{−/−} mice challenged zero or four times were harvested and lung leukocytes isolated. Following RNA isolation and cDNA conversion, samples were run on a microarray plate containing primers for a battery of transcripts. Black columns = WT untreated, white columns = IL-17\textsuperscript{−/−} untreated, dark cross-hatched columns = WT 4x challenges, light dotted columns = IL-17\textsuperscript{−/−} 4x challenge. Stars indicate significant differences between untreated and 4X challenges; starred bars indicate significant differences between mouse strains (p < .05). n = 3 for untreated mice, = 5 for 4X challenge WT mice, and = 4 for IL-17\textsuperscript{−/−} 4X challenge mice.